Integer (ITGR) 10-Q 12 May 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Apr. 03, 2015	12-May-15
Document and Entity Information [Abstract]
Entity Registrant Name	GREATBATCH, INC.
Entity Central Index Key	1114483
Document Type	10-Q
Document Period End Date	3-Apr-15
Amendment Flag	FALSE
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Current Fiscal Year End Date	0
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		25,516,718

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (Unaudited) (USD $)	Apr. 03, 2015	Jan. 02, 2015
In Thousands, unless otherwise specified
Current assets:
Cash and cash equivalents	$67,019	$76,824
Accounts receivable, net of allowance for doubtful accounts of $1.5 million in 2015 and $1.4 million in 2014	110,429	124,953
Inventories	137,989	129,242
Refundable income taxes	4,109	1,716
Deferred income taxes	6,035	6,168
Prepaid expenses and other current assets	10,733	11,780
Total current assets	336,314	350,683
Property, plant and equipment, net	151,350	144,925
Amortizing intangible assets, net	61,950	65,337
Indefinite-lived intangible assets	20,288	20,288
Goodwill	354,061	354,393
Deferred income taxes	2,704	2,626
Other assets	20,053	17,757
Total assets	946,720	956,009
Current liabilities:
Current portion of long-term debt	12,500	11,250
Accounts payable	43,074	46,436
Income taxes payable	428	2,003
Deferred income taxes	588	588
Accrued expenses	30,861	48,384
Total current liabilities	87,451	108,661
Long-term debt	172,500	176,250
Deferred income taxes	52,356	53,195
Other long-term liabilities	5,946	4,541
Total liabilities	318,253	342,647
Stockholders’ equity:
Preferred stock, $0.001 par value, authorized 100,000,000 shares; no shares issued or outstanding in 2015 or 2014	0	0
Common stock, $0.001 par value, authorized 100,000,000 shares; 25,550,215 shares issued and 25,499,234 shares outstanding in 2015; 25,099,293 shares issued and 25,070,931 shares outstanding in 2014	25	25
Additional paid-in capital	376,744	366,073
Treasury stock, at cost, 50,981 shares in 2015 and 28,362 shares in 2014	-2,456	-1,307
Retained earnings	247,456	239,448
Accumulated other comprehensive income	6,698	9,123
Total stockholders’ equity	628,467	613,362
Total liabilities and stockholders’ equity	$946,720	$956,009

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) (USD $)	Apr. 03, 2015	Jan. 02, 2015
In Millions, except Share data, unless otherwise specified
Current assets:
Allowance for doubtful accounts	$1.50	$1.40
Stockholders’ equity:
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	100,000,000	100,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	25,550,215	25,099,293
Common stock, shares outstanding	25,499,234	25,070,931
Treasury stock, shares	50,981	28,362

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Apr. 03, 2015	Apr. 04, 2014
Income Statement [Abstract]
Sales	$161,320	$174,281
Cost of sales	108,922	116,685
Gross profit	52,398	57,596
Operating expenses:
Selling, general and administrative expenses	22,609	21,755
Research, development and engineering costs, net	12,545	13,531
Other operating expenses (income), net	7,855	-214
Total operating expenses	43,009	35,072
Operating income	9,389	22,524
Interest expense	1,120	1,084
Other income, net	-1,551	-621
Income before provision for income taxes	9,820	22,061
Provision for income taxes	1,812	7,139
Net income	8,008	14,922
Earnings per share:
Basic	$0.32	$0.61
Diluted	$0.31	$0.58
Weighted average shares outstanding:
Basic	25,264	24,614
Diluted	26,219	25,694
Comprehensive Income
Net income	8,008	14,922
Foreign currency translation gain (loss)	-1,825	1,182
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax	-1,825	1,182
Net change in cash flow hedges, net of tax	-600	77
Other comprehensive income (loss)	-2,425	1,259
Comprehensive income	$5,583	$16,181

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Apr. 03, 2015	Apr. 04, 2014
Cash flows from operating activities:
Net income	$8,008	$14,922
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	9,178	9,252
Debt related amortization included in interest expense	193	192
Stock-based compensation	2,253	3,177
Other non-cash gains, net	-1,089	-3,684
Deferred income taxes	-568	-590
Changes in operating assets and liabilities:
Accounts receivable	14,311	-3,392
Inventories	-8,746	518
Prepaid expenses and other current assets	1,060	1,564
Accounts payable	-738	-2,663
Accrued expenses	-12,614	-16,733
Income taxes payable	-3,917	4,438
Net cash provided by operating activities	7,331	7,001
Cash flows from investing activities:
Acquisition of property, plant and equipment	-15,380	-5,974
Proceeds from sale of orthopaedic product lines (Note 9)	0	2,531
Purchase of cost method investment	-2,000	0
Net cash used in investing activities	-17,380	-3,443
Cash flows from financing activities:
Principal payments of long-term debt	-2,500	-2,500
Issuance of common stock	4,207	3,445
Other financing activities	-855	-1,608
Net cash provided by (used in) financing activities	852	-663
Effect of foreign currency exchange rates on cash and cash equivalents	-608	-35
Net increase (decrease) in cash and cash equivalents	-9,805	2,860
Cash and cash equivalents, beginning of period	76,824	35,465
Cash and cash equivalents, end of period	$67,019	$38,325

Condensed_Consolidated_Stateme2

Condensed Consolidated Statement of Stockholders' Equity (Unaudited) (USD $)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]
In Thousands, unless otherwise specified
Balance at Jan. 02, 2015	$613,362	$25	$366,073	($1,307)	$239,448	$9,123
Balance, shares at Jan. 02, 2015		25,099		-28
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	2,251		2,251
Net shares issued under stock incentive plans, shares		451		-95
Net shares issued under stock incentive plans	3,351	0	7,968	-4,617
Shares contributed to 401(k), shares				72
Shares contributed to 401(k) Plan	3,920		452	3,468
Net income	8,008				8,008
Total other comprehensive loss, net	-2,425					-2,425
Balance at Apr. 03, 2015	$628,467	$25	$376,744	($2,456)	$247,456	$6,698
Balance, shares at Apr. 03, 2015		25,550		-51

Basis_of_Presentation

Basis of Presentation	3 Months Ended
	Apr. 03, 2015
Accounting Policies [Abstract]
BASIS OF PRESENTATION	BASIS OF PRESENTATION
	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information (Accounting Standards Codification (“ASC”) 270, Interim Reporting) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information necessary for a full presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. In the opinion of management, the condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the results of Greatbatch, Inc. and its wholly-owned subsidiary, Greatbatch Ltd. (collectively “Greatbatch” or the “Company”), for the periods presented. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, sales, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ materially from these estimates. The January 2, 2015 condensed consolidated balance sheet data was derived from audited consolidated financial statements but does not include all disclosures required by GAAP. For further information, refer to the consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended January 2, 2015. The Company utilizes a fifty-two, fifty-three week fiscal year ending on the Friday nearest December 31. The first quarter of 2015 and 2014 each contained 13 weeks and ended on April 3, and April 4, respectively.

Acquisition

Acquisition	3 Months Ended
	Apr. 03, 2015
Business Combinations [Abstract]
ACQUISITION	ACQUISITION
	On August 12, 2014, the Company purchased all of the outstanding common stock of Centro de Construcción de Cardioestimuladores del Uruguay (“CCC”), headquartered in Montevideo, Uruguay. CCC is an active implantable neuromodulation medical device systems developer and manufacturer that produces a range of medical devices including implantable pulse generators, programmer systems, battery chargers, patient wands and leads. This acquisition allows the Company to more broadly partner with development stage medical device companies, complements the Company’s core discrete technology offerings and enhances the Company’s medical device innovation efforts.
	This transaction was accounted for under the acquisition method of accounting. Accordingly, the operating results of CCC have been included in the Company’s QiG segment from the date of acquisition. For the three months ended April 3, 2015, CCC added approximately $3.9 million to the Company’s revenue and increased the Company’s net income by $0.1 million. The aggregate purchase price of $19.8 million was funded with cash on hand.
	The cost of the acquisition was allocated to the assets acquired and liabilities assumed from CCC based on their fair values as of the closing date of the acquisition, with the amount exceeding the fair value of the net assets acquired being recorded as goodwill. The valuation of the assets acquired and liabilities assumed from CCC was finalized during the first quarter of 2015 and did not result in a material adjustment to the original valuation of net assets acquired, including goodwill.
	The following table summarizes the allocation of the CCC purchase price to the assets acquired and liabilities assumed as of the acquisition date (in thousands):
	Assets acquired
	Current assets	$	10,670
	Property, plant and equipment	1,131
	Amortizing intangible assets	6,100
	Goodwill	8,296
	Total assets acquired	26,197
	Liabilities assumed
	Current liabilities	4,842
	Deferred income taxes	1,590
	Total liabilities assumed	6,432
	Net assets acquired	$	19,765
	The fair values of the assets acquired were determined using one of three valuation approaches: market, income or cost. The selection of a particular method for a given asset depended on the reliability of available data and the nature of the asset, among other considerations.
	The market approach estimates the value for a subject asset based on available market pricing for comparable assets. The income approach estimates the value for a subject asset based on the present value of cash flows projected to be generated by the asset. The projected cash flows were discounted at a required rate of return that reflects the relative risk of the asset and the time value of money. The projected cash flows for each asset considered multiple factors from the perspective of a marketplace participant including revenue projections from existing customers, attrition trends, technology life-cycle assumptions, marginal tax rates and expected profit margins giving consideration to historical and expected margins. The cost approach estimates the value for a subject asset based on the cost to replace the asset and reflects the estimated reproduction or replacement cost for the asset, less an allowance for loss in value due to depreciation or obsolescence, with specific consideration given to economic obsolescence if indicated. These fair value measurement approaches are based on significant unobservable inputs, including management estimates and assumptions.
	Current Assets and Liabilities – The fair value of current assets and liabilities, excluding inventory, was assumed to approximate their carrying value as of the acquisition date due to the short-term nature of these assets and liabilities.
	The fair value of in-process and finished goods inventory acquired was estimated by applying a version of the market approach called the comparable sales method. This approach estimates the fair value of the assets by calculating the potential revenue generated from selling the inventory and subtracting from it the costs related to the completion and sale of that inventory and a reasonable profit allowance. Based upon this methodology, the Company recorded the inventory acquired at fair value resulting in an increase in inventory of $0.3 million.
	Intangible Assets – The purchase price was allocated to intangible assets as follows (dollars in thousands):
	Amortizing Intangible Assets		Fair			Weighted	Weighted
			Value			Average	Average
			Assigned			Amortization	Discount
						Period (Years)	Rate
	Technology		$	1,400		10	18%
	Customer lists		4,600			10	18%
	Trademarks and tradenames		100			2	18%
			$	6,100		10	18%
	Technology – Technology consists of technical processes, unpatented technology, manufacturing know-how, trade secrets and the understanding with respect to products or processes that have been developed by CCC and that will be leveraged in current and future products. The fair value of technology acquired was determined utilizing the relief from royalty method, a form of the income approach, with a royalty rate of 3%. The weighted average amortization period of the technology is based upon management’s estimate of the product life cycle associated with the technology before they will be replaced by new technologies.
	Customer Lists – Customer lists represent the estimated fair value of non-contractual customer relationships CCC has as of the acquisition date. The primary customers of CCC include medical device companies in various geographic locations around the world. These relationships were valued separately from goodwill at the amount that an independent third party would be willing to pay for these relationships. The fair value of customer lists was determined using the multi-period excess-earnings method, a form of the income approach. The weighted average amortization period of the existing customer base was based upon the historical customer annual attrition rate of 15%, as well as management’s understanding of the industry and product life cycles.
	Trademarks and Tradenames – Trademarks and tradenames represent the estimated fair value of corporate and product names acquired from CCC. These tradenames were valued separately from goodwill at the amount that an independent third party would be willing to pay for use of these names. The fair value of the trademarks and tradenames was determined by utilizing the relief from royalty method, a form of the income approach, with a 0.5% royalty rate.
	Goodwill – The excess of the purchase price over the fair value of net tangible and intangible assets acquired and liabilities assumed was allocated to goodwill. Various factors contributed to the establishment of goodwill, including: the value of CCC’s highly trained assembled work force and management team; the incremental value that CCC’s technology will bring to QiG’s medical devices; and the expected revenue growth over time that is attributable to increased market penetration from future products and customers for Greatbatch Medical. The goodwill acquired in connection with the CCC acquisition was allocated to the QiG business segment and is not deductible for tax purposes.
	Pro Forma Results (Unaudited)
	The following unaudited pro forma information presents the consolidated results of operations of the Company and CCC as if that acquisition occurred as of the beginning of fiscal year 2013 (in thousands, except per share amounts):
		Three Months Ended
		3-Apr-15			4-Apr-14
	Sales	$	161,320		$	177,709
	Net income	8,008			15,258
	Earnings per share:
	Basic	$	0.32		$	0.62
	Diluted	$	0.31		$	0.59
	The results prior to the acquisition date have been adjusted to include the pro forma impact of the amortization of acquired intangible assets based on the purchase price allocations and the impact of income taxes on the pro forma adjustments utilizing the applicable statutory tax rate. The unaudited pro forma consolidated basic and diluted earnings per share calculations are based on the consolidated basic and diluted weighted average shares of Greatbatch.
	The unaudited pro forma results are presented for illustrative purposes only and do not reflect the realization of potential cost savings or any related integration costs. Certain cost savings may result from the acquisition; however, there can be no assurance that these cost savings will be achieved. These pro forma results do not purport to be indicative of the results that would have been obtained in the periods presented, or to be indicative of results that may be obtained in the future.

Supplemental_Cash_Flow_Informa

Supplemental Cash Flow Information	3 Months Ended
	Apr. 03, 2015
Supplemental Cash Flow Elements [Abstract]
SUPPLEMENTAL CASH FLOW INFORMATION	SUPPLEMENTAL CASH FLOW INFORMATION
		Three Months Ended
	(in thousands)	April 3, 2015		April 4, 2014
	Noncash investing and financing activities:
	Common stock contributed to 401(k) Plan	$	3,920	$	4,341
	Property, plant and equipment purchases included in accounts payable	943		1,180

Inventories

Inventories	3 Months Ended
	Apr. 03, 2015
Inventory Disclosure [Abstract]
INVENTORIES	INVENTORIES
	Inventories are comprised of the following (in thousands):
		As of
		3-Apr-15		2-Jan-15
	Raw materials	$	76,738	$	73,354
	Work-in-process	43,402		38,930
	Finished goods	17,849		16,958
	Total	$	137,989	$	129,242

Intangible_Assets

Intangible Assets	3 Months Ended
	Apr. 03, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS	INTANGIBLE ASSETS
	Amortizing intangible assets are comprised of the following (in thousands):
		Gross			Accumulated			Foreign			Net
		Carrying			Amortization			Currency			Carrying
		Amount						Translation			Amount
	At April 3, 2015
	Purchased technology and patents	$	95,776		$	(77,468	)	$	1,966		$	20,274
	Customer lists	72,857			(33,208		)	1,374			41,023
	Other	4,534			(4,684		)	803			653
	Total amortizing intangible assets	$	173,167		$	(115,360	)	$	4,143		$	61,950
	At January 2, 2015
	Purchased technology and patents	$	95,776		$	(75,894	)	$	1,966		$	21,848
	Customer lists	72,857			(31,460		)	1,374			42,771
	Other	4,534			(4,619		)	803			718
	Total amortizing intangible assets	$	173,167		$	(111,973	)	$	4,143		$	65,337
	Aggregate intangible asset amortization expense is comprised of the following (in thousands):
		Three Months Ended
		3-Apr-15			4-Apr-14
	Cost of sales	$	1,471		$	1,563
	Selling, general and administrative expenses	1,813			1,717
	Research, development and engineering costs, net	103			201
	Total intangible asset amortization expense	$	3,387		$	3,481
	Estimated future intangible asset amortization expense based on the current carrying value is as follows (in thousands):
		Estimated
		Amortization
		Expense
	Remainder of 2015	$	9,600
	2016	10,795
	2017	9,520
	2018	7,114
	2019	5,431
	Thereafter	19,490
	Total estimated amortization expense	$	61,950
	Indefinite-lived intangible assets are comprised of the following (in thousands):
		Trademarks
		and
		Tradenames
	At January 2, 2015	$	20,288
	At April 3, 2015	$	20,288
	The change in goodwill is as follows (in thousands):
		Greatbatch Medical			QiG			Total
	At January 2, 2015	$	304,297		$	50,096		$	354,393
	Foreign currency translation	(332		)	—			(332		)
	At April 3, 2015	$	303,965		$	50,096		$	354,061

Debt

Debt	3 Months Ended
	Apr. 03, 2015
Debt Disclosure [Abstract]
DEBT	DEBT
	Long-term debt is comprised of the following (in thousands):
		As of
		3-Apr-15				2-Jan-15
	Variable rate term loan	$	185,000			$	187,500
	Revolving line of credit	—				—
	Total debt	185,000				187,500
	Less current portion of long-term debt	12,500				11,250
	Total long-term debt	$	172,500			$	176,250
	Credit Facility – The Company has a credit facility (the “Credit Facility”) that provides a $300 million revolving credit facility (the “Revolving Credit Facility”), a $200 million term loan (the “Term Loan”), a $15 million letter of credit subfacility, and a $15 million swingline subfacility. The Revolving Credit Facility can be increased by $200 million upon the Company’s request and approval by the lenders. The Revolving Credit Facility has a maturity date of September 20, 2018, which may be extended to September 20, 2019 upon notice by the Company and subject to certain conditions. The principal of the Term Loan is payable in quarterly installments as specified in the Credit Facility until its maturity date of September 20, 2019 when the unpaid balance is due in full.
	The Credit Facility is secured by the Company’s non-realty assets including cash, accounts receivable and inventories. Interest rates on the Revolving Credit Facility and Term Loan are, at the Company’s option either at: (i) the prime rate plus the applicable margin, which ranges between 0.0% and 0.75%, based on the Company’s total leverage ratio or (ii) the applicable LIBOR rate plus the applicable margin, which ranges between 1.375% and 2.75%, based on the Company’s total leverage ratio. Loans under the swingline subfacility will bear interest at the prime rate plus the applicable margin, which ranges between 0.0% and 0.75%, based on the Company’s total leverage ratio. The Company is also required to pay a commitment fee, which varies between 0.175% and 0.25%, depending on the Company’s total leverage ratio.
	The Credit Facility contains limitations on the incurrence of indebtedness, liens and licensing of intellectual property, investments, and certain payments. The Credit Facility permits the Company to engage in the following activities up to an aggregate amount of $300 million: 1) permitted acquisitions in the aggregate not to exceed $250 million; 2) other investments in the aggregate not to exceed $100 million; 3) stock repurchases and dividends not to exceed $150 million in the aggregate; and 4) investments in foreign subsidiaries not to exceed $20 million in the aggregate. At any time that the total leverage ratio of the Company for the two most recently ended fiscal quarters is less than 2.75 to 1.0, the Company may make an election to reset each of the amounts specified above. Additionally, these limitations can be waived upon the Company’s request and approval of a majority of the lenders. As of April 3, 2015, the Company had available to it 100% of the above limits except for the aggregate, acquisitions and other investments limit which are now $275 million, $230 million, and $95 million, respectively.
	The Credit Facility requires the Company to maintain a rolling four quarter ratio of adjusted EBITDA to interest expense of at least 3.0 to 1.0, and a total leverage ratio of not greater than 4.5 to 1.0 decreasing to not greater than 4.25 to 1.0 after January 2, 2016. The calculation of adjusted EBITDA and total leverage ratio excludes non-cash charges, extraordinary, unusual, or non-recurring expenses or losses, non-cash stock-based compensation, and non-recurring expenses or charges incurred in connection with permitted acquisitions. As of April 3, 2015, the Company was in compliance with all covenants under the Credit Facility.
	The Credit Facility contains customary events of default. Upon the occurrence and during the continuance of an event of default, a majority of the lenders may declare the outstanding advances and all other obligations under the Credit Facility immediately due and payable.
	As of April 3, 2015, the weighted average interest rate on borrowings under the Credit Facility, which does not take into account the impact of the Company’s interest rate swap, was 1.57%. As of April 3, 2015, the Company had $300 million of borrowing capacity available under the Revolving Credit Facility. This borrowing capacity may vary from period to period based upon the debt and EBITDA levels of the Company, which impacts the covenant calculations described above.
	Interest Rate Swaps – From time to time, the Company enters into interest rate swap agreements in order to hedge against potential changes in cash flows on the outstanding borrowings on the Credit Facility. The variable rate received on the interest rate swaps and the variable rate paid on the debt have the same rate of interest, excluding the credit spread, indexed to the one-month LIBOR rate and reset and pay interest on the same date. During 2012, the Company entered into a three-year $150 million interest rate swap, which amortizes $50 million per year. During 2014, the Company entered into an additional interest rate swap. The first $45 million of notional amount of the swap was effective February 20, 2015, and the second $45 million of notional amount is effective February 22, 2016. The notional amount of the swap amortizes $10 million per year beginning on February 21, 2017, with the remaining settled on the termination date of the swap agreement on September 20, 2019. These swaps are being accounted for as cash flow hedges.
	Information regarding the Company’s outstanding interest rate swaps as of April 3, 2015 is as follows (dollars in thousands):
	Instrument		Type of		Notional			Start	End	Pay		Current		Fair Value			Balance
			Hedge		Amount			Date	Date	Fixed		Receive					Sheet Location
										Rate		Floating
												Rate
	Interest rate swap		Cash flow		$	50,000		13-Feb	16-Feb	0.573	%	0.176	%	$	(127	)	Accrued Expenses
	Interest rate swap		Cash flow		$	90,000		15-Feb	19-Sep	1.921	%	0.176	%	$	(2,194	)	Other Long-Term Liabilities
	The estimated fair value of the interest rate swap agreements represents the amount the Company expects to receive (pay) to terminate the contracts. No portion of the change in fair value of the Company’s interest rate swaps during the three months ended April 3, 2015 and April 4, 2014 were considered ineffective. The amount recorded as Interest Expense during the three months ended April 3, 2015 and April 4, 2014 related to the Company’s interest rate swaps was $0.2 million and $0.1 million, respectively.
	The expected future minimum principal payments under the Term Loan as of April 3, 2015 are as follows (in thousands):
	Remainder of 2015	$	8,750
	2016	16,250
	2017	20,000
	2018	20,000
	2019	120,000
	Total	$	185,000
	Deferred Financing Fees – The change in deferred financing fees is as follows (in thousands):
	At January 2, 2015	$	3,087
	Amortization during the period	(193		)
	At April 3, 2015	$	2,894

Benefit_Plans

Benefit Plans	3 Months Ended
	Apr. 03, 2015
Defined Benefit Pension Plans and Defined Benefit Postretirement Plans Disclosure [Abstract]
BENEFIT PLANS	BENEFIT PLANS
	The Company is required to provide its employees located in Switzerland, Mexico, and France certain statutorily mandated defined benefits. Under these plans, benefits accrue to employees based upon years of service, position, age, and compensation. The defined benefit pension plan provided to the Company’s employees located in Switzerland is a funded contributory plan, while the plans that provide benefits to the Company’s employees located in Mexico and France are unfunded and noncontributory. The liability and corresponding expense related to these benefit plans is based on actuarial computations of current and future benefits for employees.
	The change in net defined benefit plan liability is as follows (in thousands):
	At January 2, 2015	$	2,406
	Net defined benefit cost	105
	Foreign currency translation	(176		)
	At April 3, 2015	$	2,335
	Net defined benefit cost is comprised of the following (in thousands):
		Three Months Ended
		3-Apr-15			4-Apr-14
	Service cost	$	79		$	52
	Interest cost	15			19
	Amortization of net loss	14			6
	Expected return on plan assets	(3		)	—
	Net defined benefit cost	$	105		$	77

StockBased_Compensation

Stock-Based Compensation	3 Months Ended
	Apr. 03, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
STOCK-BASED COMPENSATION	STOCK-BASED COMPENSATION
	The components and classification of stock-based compensation expense were as follows (in thousands):
		Three Months Ended
		3-Apr-15				4-Apr-14
	Stock options	$	619			$	604
	Restricted stock and restricted stock units	1,634				1,557
	401(k) Plan stock contribution	—				1,016
	Total stock-based compensation expense	$	2,253			$	3,177
	Cost of sales	$	260			$	911
	Selling, general and administrative expenses	1,761				1,923
	Research, development and engineering costs, net	232				343
	Total stock-based compensation expense	$	2,253			$	3,177
	The weighted average fair value and assumptions used to value options granted are as follows:
		Three Months Ended
		3-Apr-15				4-Apr-14
	Weighted average fair value	$	12.07			$	16.41
	Risk-free interest rate	1.55		%		1.73		%
	Expected volatility	26		%		39		%
	Expected life (in years)	5				5
	Expected dividend yield	—		%		—		%
	The following table summarizes time-vested stock option activity:
		Number of			Weighted				Weighted	Aggregate
		Time-Vested			Average				Average	Intrinsic
		Stock			Exercise				Remaining	Value
		Options			Price				Contractual	(In Millions)
									Life
									(In Years)
	Outstanding at January 2, 2015	1,471,498			$	25.32
	Granted	265,841			48.68
	Exercised	(159,229	)		23.2
	Forfeited or expired	(15,410	)		33.99
	Outstanding at April 3, 2015	1,562,700			$	29.43			6.6	$	42.7
	Exercisable at April 3, 2015	1,123,451			$	24.1			5.6	$	36.6
	The following table summarizes performance-vested stock option activity:
		Number of			Weighted				Weighted	Aggregate
		Performance-			Average				Average	Intrinsic
		Vested Stock			Exercise				Remaining	Value
		Options			Price				Contractual	(In Millions)
									Life
									(In Years)
	Outstanding at January 2, 2015	118,839			$	23.24
	Exercised	(22,637	)		22.71
	Outstanding at April 3, 2015	96,202			$	23.36			2.8	$	3.2
	Exercisable at April 3, 2015	96,202			$	23.36			2.8	$	3.2
	The following table summarizes time-vested restricted stock and restricted stock unit activity:
		Time-Vested			Weighted
		Activity			Average
					Fair Value
	Nonvested at January 2, 2015	67,832			$	36.22
	Granted	36,182			49.04
	Vested	(3,500	)		48.63
	Forfeited	(4,106	)		40.78
	Nonvested at April 3, 2015	96,408			$	40.39
	The following table summarizes performance-vested restricted stock and restricted stock unit activity:
		Performance-			Weighted
		Vested			Average
		Activity			Fair Value
	Nonvested at January 2, 2015	716,163			$	19.57
	Granted	179,940			32.92
	Vested	(270,198	)		15.3
	Forfeited	(14,585	)		24.67
	Nonvested at April 3, 2015	611,320			$	25.27

Other_Operating_Income_Expense

Other Operating (Income) Expenses, Net	3 Months Ended
	Apr. 03, 2015
Other Income and Expenses [Abstract]
OTHER OPERATING (INCOME) EXPENSES, NET	OTHER OPERATING EXPENSES (INCOME), NET
	Other Operating Expenses (Income), Net is comprised of the following (in thousands):
		Three Months Ended
		3-Apr-15			4-Apr-14
	2014 investments in capacity and capabilities	$	6,455		$	—
	Orthopaedic optimization costs (income)	473			(1,157		)
	2013 operating unit realignment	—			1,003
	Other consolidation and optimization income, net	—			(61		)
	Acquisition and integration costs (income)	66			(428		)
	Asset dispositions, severance and other	861			429
		$	7,855		$	(214	)
	2014 investments in capacity and capabilities. In 2014, the Company announced several initiatives to invest in capacity and capabilities and to better align its resources to meet its customers’ needs and drive organic growth and profitability. These included the following:
	•	Functions currently performed at the Company’s facility in Plymouth, MN to manufacture catheters and introducers will transfer into the Company’s existing facility in Tijuana, Mexico. This initiative is expected to be substantially completed by the first half of 2016 and is dependent upon our customer’s validation and qualification of the transferred products.
	•	Functions currently performed at the Company’s facilities in Beaverton, OR and Raynham, MA to manufacture products for the portable medical market will transfer to a new facility in Tijuana, Mexico. This initiative is expected to be substantially completed by the end of 2015 and is dependent upon our customer’s validation and qualification of the transferred products. Products currently manufactured at the Beaverton facility, which do not serve the portable medical market, are planned to transfer to the Company’s Raynham facility.
	•	The design engineering responsibilities previously performed at the Company’s Cleveland, OH facility was transferred to the Company’s facilities in Minnesota in 2014.
	•	Establishing a commercial hub at the Company’s global headquarters in Frisco, Texas. This initiative built upon the investment the Company has made in its global sales and marketing function and is expected to be completed in the first half of 2015.
	The total capital investment expected for these initiatives is between $25.0 million and $27.0 million, of which $13.0 million has been expended through April 3, 2015. Total restructuring charges expected to be incurred in connection with this realignment are between $29.0 million and $34.0 million, of which $15.4 million has been incurred through April 3, 2015. Expenses related to this initiative are recorded within the applicable segment and corporate cost centers that the expenditures relate to and include the following:
	•Severance and retention: $7.0 million - $9.0 million;
	•Accelerated depreciation and asset write-offs: $2.0 million - $3.0 million; and
	•Other: $20.0 million - $22.0 million
	Other costs primarily consist of costs to relocate certain equipment and personnel, duplicate personnel costs, disposal and travel expenditures. All expenses are cash expenditures, except accelerated depreciation and asset write-offs.
	The change in accrued liabilities related to the 2014 investments in capacity and capabilities is as follows (in thousands):
		Severance and			Accelerated			Other			Total
		Retention			Depreciation/Asset
					Write-offs
	At January 2, 2015	$	1,163		$	—		$	1,066		$	2,229
	Restructuring charges	549			—			5,906			6,455
	Cash payments	(100		)	—			(5,590		)	(5,690		)
	At April 3, 2015	$	1,612		$	—		$	1,382		$	2,994
	Orthopaedic optimization costs (income). In 2010, the Company began updating its Indianapolis, IN facility to streamline operations, consolidate two buildings, increase capacity, further expand capabilities and reduce dependence on outside suppliers. This initiative was completed in 2011.
	In 2011, the Company began construction on an orthopaedic manufacturing facility in Fort Wayne, IN and transferred manufacturing operations being performed at its Columbia City, IN location into this new facility. This initiative was completed in 2012.
	During 2012, the Company transferred manufacturing and development operations performed at its facilities in Orvin and Corgemont, Switzerland into existing facilities in Fort Wayne, IN and Tijuana, Mexico. In connection with this consolidation, in 2013, the Company sold assets related to certain non-core Swiss orthopaedic product lines to an independent third party. The purchase agreement provided the Company with an earn-out payment based upon the amount of inventory consumed by the purchaser within one year after the close of the transaction. As a result of this earn out, a gain of $2.5 million was recorded in Other Operating Expenses (Income), Net in the first quarter of 2014. During 2014, the Company transferred $2.1 million of assets relating to the Company’s Orvin, Switzerland property to held for sale and recognized a $0.4 million impairment charge in the fourth quarter of 2014.
	During 2013, the Company began a project to expand its Chaumont, France facility in order to enhance its capabilities and fulfill larger volume customer supply agreements. This initiative is expected to be completed over the next three years.
	The total capital investment expected to be incurred for these initiatives is between $30 million and $35 million, of which $25.3 million has been expended through April 3, 2015. Total expense expected to be incurred for these initiatives is between $45 million and $48 million, of which $43.0 million has been incurred through April 3, 2015. All expenses have been and will be recorded within the Greatbatch Medical segment and are expected to include the following:
	•	Severance and retention: approximately $11 million;
	•	Accelerated depreciation and asset write-offs: approximately $13 million; and
	•	Other: $21 million – $24 million
	Other costs include production inefficiencies, moving, revalidation, personnel, training, and travel costs associated with these consolidation projects. All expenses are cash expenditures, except accelerated depreciation and asset write-offs.
	The change in accrued liabilities related to the orthopaedic facility optimization is as follows (in thousands):
		Severance			Accelerated			Other			Total
		and			Depreciation/Asset
		Retention			Write-offs
	At January 2, 2015	$	—		$	—		$	287		$	287
	Restructuring charges	—			—			473			473
	Cash payments	—			—			(473		)	(473		)
	At April 3, 2015	$	—		$	—		$	287		$	287
	2013 operating unit realignment. In 2013, the Company initiated a plan to realign its operating structure in order to optimize its continued focus on profitable growth. As part of this initiative, the sales and marketing and operations groups of its former Implantable Medical and Electrochem Solutions reportable segments were combined into one sales and marketing group and one operations group each serving Greatbatch Medical. This initiative was completed during 2014. Total restructuring charges incurred in connection with this realignment were $6.6 million. Expenses related to this initiative were recorded within the applicable segment that the expenditures relate to and included the following:
	•Severance and retention: $5.0 million; and
	•Other: $1.6 million
	Other costs primarily consisted of relocation and travel expenditures. All expenses were cash expenditures.
	Asset dispositions, severance and other. During 2015 and 2014, the Company recorded losses in connection with various asset disposals and/or write-downs. During the first quarter of 2015, the Company initiated plans to spin-off Algostim, LLC (“Algostim”). Algostim is a subsidiary of QiG Group (“QiG”), which was established in 2008 to design and develop a broad-based neurostimulation platform. Algostim’s Algovita Spinal Cord Stimulation system is the first application of the platform, with additional QiG applications currently in development. During the first three months of 2015, the Company incurred $0.5 million of legal and professional costs in connection with the proposed spin-off. Expenses related to this initiative will be recorded within the applicable segment and corporate cost centers that the expenditures relate to. Transaction related costs for the spin-off are estimated to be between $8 million to $12 million. Refer to Note 15 “Business Segment, Geographic and Concentration Risk Information” for additional discussion on the proposed spin-off. During 2014, the Company recorded charges in connection with its business reorganization to align its contract manufacturing operations. Those costs primarily related to consulting and IT development projects, which were completed in the fourth quarter of 2014.

Income_Taxes

Income Taxes	3 Months Ended
	Apr. 03, 2015
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES
	The income tax provision for interim periods is determined using an estimate of the annual effective tax rate, adjusted for discrete items, if any, that are taken into account in the relevant period. Each quarter, the estimate of the annual effective tax rate is updated, and if the estimated effective tax rate changes, a cumulative adjustment is made. There is a potential for volatility of the effective tax rate due to several factors, including changes in the mix of the pre-tax income and the jurisdictions to which it relates, changes in tax laws and foreign tax holidays, business reorganizations, settlements with taxing authorities and foreign currency fluctuations.
	As of April 3, 2015, the balance of unrecognized tax benefits is approximately $1.9 million. It is reasonably possible that a reduction of up to $0.5 million of the balance of unrecognized tax benefits may occur within the next twelve months as a result of potential audit settlements. Approximately $1.5 million of the balance of unrecognized tax benefits would favorably impact the effective tax rate, net of federal benefit on state issues, if recognized.

Commitments_And_Contingencies

Commitments And Contingencies

3 Months Ended

Apr. 03, 2015

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES

Litigation – On December 21, 2012, the Company and several other unaffiliated parties were named as defendants in a personal injury and wrongful death action filed in the 113th Judicial District Court of Harris County, Texas. The complaint sought damages alleging marketing and product defects and failure to warn, negligence and gross negligence relating to a product the Company manufactured and sold to a customer, one of the other named defendants. The Company’s customer, in turn, incorporated the Greatbatch product into its own product which it sold to a third party, another named defendant. The Company was indemnified by its customer against any loss in the matter. On December 3, 2014, the District Court granted the Company’s motion for summary judgment and dismissed all claims against the Company. That ruling was subject to appeal by the plaintiffs. In February 2015, the plaintiffs entered into a settlement agreement with the Company’s customer that released the Company from all claims for liability in the matter.

The Company is a party to various other legal actions arising in the normal course of business. While the Company does not expect that the ultimate resolution of any of these pending actions will have a material effect on its consolidated results of operations, financial position, or cash flows, litigation is subject to inherent uncertainties. As such, there can be no assurance that any pending legal action, which the Company currently believes to be immaterial, does not become material in the future.

Product Warranties – The Company generally warrants that its products will meet customer specifications and will be free from defects in materials and workmanship. The change in product warranty liability was comprised of the following (in thousands):

At January 2, 2015

$

660

Additions to warranty reserve

691

Warranty claims paid

(72

)

At April 3, 2015

$

1,279

Purchase Commitments – Contractual obligations for purchase of goods or services are defined as agreements that are enforceable and legally binding on the Company and that specify all significant terms, including: fixed or minimum quantities to be purchased; fixed, minimum, or variable price provisions; and the approximate timing of the transaction. The Company’s purchase orders are normally based on its current manufacturing needs and are fulfilled by its vendors within short time horizons. The Company also enters into blanket orders with vendors that have preferred pricing and terms; however, these orders are normally cancelable without penalty. As of April 3, 2015, the total contractual obligation related to such expenditures is approximately $40.6 million and will primarily be financed by existing cash and cash equivalents, cash generated from operations, or the Credit Facility. The Company also enters into contracts for outsourced services; however, the obligations under these contracts were not significant and the contracts generally contain clauses allowing for cancellation without significant penalty.

Operating Leases – The Company is a party to various operating lease agreements for buildings, machinery, equipment, and software. The Company primarily leases buildings, which accounts for the majority of the future lease payments. Minimum future estimated operating lease expenses are as follows (in thousands):

Remainder of 2015

$

4,525

2016

6,006

2017

3,909

2018

3,489

2019

3,418

Thereafter

13,938

Total estimated operating lease expense

$

35,285

Workers’ Compensation Trust – The Company was a member of a group self-insurance trust that provided workers’ compensation benefits to employees of the Company in Western New York (the “Trust”). Under the Trust agreement, each participating organization has joint and several liability for Trust obligations if the assets of the Trust are not sufficient to cover those obligations. During 2011, the Company was notified by the Trust of its intentions to cease operations at the end of 2011 and was assessed a pro-rata share of future costs related to the Trust. Based on actual experience, the Company could receive a refund or be assessed additional contributions for workers’ compensation claims insured by the Trust. Since 2011, the Company has utilized a traditional insurance provider for workers’ compensation coverage.

Foreign Currency Contracts – The Company has entered into forward contracts to purchase Mexican pesos in order to hedge the risk of peso-denominated payments associated with operations at its Tijuana, Mexico facility. The impact to the Company’s results of operations from these forward contracts was as follows (in thousands):

Three Months Ended

3-Apr-15

4-Apr-14

Addition (reduction) in cost of sales

$

244

$

(164

)

Ineffective portion of change in fair value

—

—

Information regarding outstanding foreign currency contracts as of April 3, 2015 is as follows (dollars in thousands):

Instrument

Type of

Aggregate

Start

End

$/Peso

Fair

Balance Sheet Location

Hedge

Notional

Date

Date

Value

Amount

FX Contract

Cash flow

$12,660

15-Jan

15-Dec

0.0734

($1,128)

Accrued Expenses

FX Contract

Cash flow

$2,360

15-Mar

15-Dec

0.0656

$45

Other Current Assets

FX Contract

Cash flow

$15,081

16-Jan

16-Dec

0.0656

($77)

Other Long-Term Liabilities

Self-Insured Medical Plan – The Company self-funds the medical insurance coverage provided to its U.S. based employees. The Company has specific stop loss coverage for claims incurred during 2015 exceeding $250 thousand per associate with no annual maximum aggregate stop loss coverage. As of April 3, 2015, the Company had $1.5 million accrued related to the self-insurance of its medical plan. This accrual is recorded in Accrued Expenses in the Condensed Consolidated Balance Sheet and is primarily based upon claim history.

Earnings_Per_Share_EPS

Earnings Per Share (EPS)	3 Months Ended
	Apr. 03, 2015
Earnings Per Share [Abstract]
EARNINGS PER SHARE (EPS)	EARNINGS PER SHARE (“EPS”)
	The following table illustrates the calculation of Basic and Diluted EPS (in thousands, except per share amounts):
		Three Months Ended
		3-Apr-15			4-Apr-14
	Numerator for basic and diluted EPS:
	Net income	$	8,008		$	14,922
	Denominator for basic EPS:
	Weighted average shares outstanding	25,264			24,614
	Effect of dilutive securities:
	Stock options, restricted stock and restricted stock units	955			1,080
	Denominator for diluted EPS	26,219			25,694
	Basic EPS	$	0.32		$	0.61
	Diluted EPS	$	0.31		$	0.58
	The diluted weighted average share calculations do not include the following securities, which are not dilutive to the EPS calculations or the performance criteria have not been met:
		Three Months Ended
		3-Apr-15		4-Apr-14
	Time-vested stock options, restricted stock and restricted stock units	266,000		193,000
	Performance-vested restricted stock units	11,900		5,900

Accumulated_Other_Comprehensiv

Accumulated Other Comprehensive Income	3 Months Ended
	Apr. 03, 2015
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
ACCUMULATED OTHER COMPREHENSIVE INCOME	ACCUMULATED OTHER COMPREHENSIVE INCOME
	Accumulated Other Comprehensive Income is comprised of the following (in thousands):
		Defined			Cash			Foreign			Total			Tax			Net-of-Tax
		Benefit			Flow			Currency			Pre-Tax						Amount
		Plan			Hedges			Translation			Amount
		Liability						Adjustment
	At January 2, 2015	$	(1,181	)	$	(2,558	)	$	11,450		$	7,711		$	1,412		$	9,123
	Unrealized loss on cash flow hedges	—			(1,347		)	—			(1,347		)	470			(877		)
	Realized loss on foreign currency hedges	—			244			—			244			(85		)	159
	Realized loss on interest rate swap hedges	—			181			—			181			(63		)	118
	Foreign currency translation loss	—			—			(1,825		)	(1,825		)	—			(1,825		)
	At April 3, 2015	$	(1,181	)	$	(3,480	)	$	9,625		$	4,964		$	1,734		$	6,698
		Defined			Cash			Foreign			Total			Tax			Net-of-Tax
		Benefit			Flow			Currency			Pre-Tax						Amount
		Plan			Hedges			Translation			Amount
		Liability						Adjustment
	At January 3, 2014	$	(672	)	$	(468	)	$	14,952		$	13,812		$	546		$	14,358
	Unrealized gain on cash flow hedges	—			150			—			150			(53		)	97
	Realized gain on foreign currency hedges	—			(164		)	—			(164		)	57			(107		)
	Realized loss on interest rate swap hedges	—			132			—			132			(45		)	87
	Foreign currency translation gain	—			—			1,182			1,182			—			1,182
	At April 4, 2014	$	(672	)	$	(350	)	$	16,134		$	15,112		$	505		$	15,617
	The realized (gain) loss relating to the Company’s foreign currency and interest rate swap hedges were reclassified from Accumulated Other Comprehensive Income and included in Cost of Sales and Interest Expense, respectively, in the Condensed Consolidated Statements of Operations.

Fair_Value_Measurements

Fair Value Measurements	3 Months Ended
	Apr. 03, 2015
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	FAIR VALUE MEASUREMENTS
	Assets and Liabilities Measured at Fair Value on a Recurring Basis
	Fair value measurement standards apply to certain financial assets and liabilities that are measured at fair value on a recurring basis (each reporting period). For the Company, these financial assets and liabilities include its derivative instruments. The Company does not have any nonfinancial assets or liabilities that are measured at fair value on a recurring basis.
	Foreign Currency Contracts – The fair value of foreign currency contracts are determined through the use of cash flow models that utilize observable market data inputs to estimate fair value. These observable market data inputs include foreign exchange rate and credit spread curves. In addition, the Company received fair value estimates from the foreign currency contract counterparty to verify the reasonableness of the Company’s estimates. The Company’s foreign currency contracts are categorized in Level 2 of the fair value hierarchy. The fair value of the Company’s foreign currency contracts will be realized as Cost of Sales as the inventory, which the contracts are hedging the cash flows to produce, is sold, of which approximately $1.1 million is expected to be realized within the next twelve months.
	Interest Rate Swaps – The fair value of the Company’s interest rate swaps outstanding at April 3, 2015 were determined through the use of a cash flow model that utilizes observable market data inputs. These observable market data inputs include LIBOR, swap rates, and credit spread curves. In addition, the Company received a fair value estimate from the interest rate swap counterparty to verify the reasonableness of the Company’s estimate. This fair value calculation was categorized in Level 2 of the fair value hierarchy. The fair value of the Company’s interest rate swaps will be realized as Interest Expense as interest on the Credit Facility is accrued.
	The following table provides information regarding assets and liabilities recorded at fair value on a recurring basis (in thousands):
		Fair Value Measurements Using
		At		Quoted		Significant		Significant
		April 3,		Prices in		Other		Unobservable
				Active Markets		Observable		Inputs
				for Identical		Inputs
				Assets
	Description	2015		(Level 1)		(Level 2)		(Level 3)
	Assets
	Foreign currency contracts (Note 11)	$	45	$	—	$	45	$	—
	Liabilities
	Foreign currency contracts	$	1,205	$	—	$	1,205	$	—
	Interest rate swap (Note 6)	2,321		—		2,321		—
	Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis
	Fair value standards also apply to certain assets and liabilities that are measured at fair value on a nonrecurring basis. The carrying amounts of cash, accounts receivable, accounts payable, accrued expenses, and current portion of long-term debt approximate fair value because of the short-term nature of these items. As of April 3, 2015, the fair value of the Company’s variable rate long-term debt approximates its carrying value and is categorized in Level 2 of the fair value hierarchy. A summary of the valuation methodologies for assets and liabilities measured on a nonrecurring basis is as follows:
	Long-lived Assets – The Company reviews the carrying amount of its long-lived assets to be held and used, other than goodwill and indefinite-lived intangible assets, for potential impairment whenever certain indicators are present such as: a significant decrease in the market price of the asset or asset group; a significant change in the extent or manner in which the long-lived asset or asset group is being used or in its physical condition; a significant change in legal factors or in the business climate that could affect the value of the long-lived asset or asset group, including an action or assessment by a regulator; an accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction; a current-period operating or cash flow loss combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with the use of the long-lived asset or asset group; or a current expectation that, more likely than not, a long-lived asset or asset group will be sold or otherwise disposed of significantly before the end of its previously estimated useful life. The term more likely than not refers to a level of likelihood that is more than 50 percent.
	Potential recoverability is measured by comparing the carrying amount of the asset or asset group to its related total future undiscounted cash flows. If the carrying value is not recoverable, the asset or asset group is considered to be impaired. Impairment is measured by comparing the asset or asset group’s carrying amount to its fair value. When it is determined that useful lives are shorter than originally estimated, and no impairment is present, the rate of depreciation is accelerated in order to fully depreciate the assets over their new shorter useful lives. The Company did not record any impairment charges related to its long-lived assets during the first three months of 2015 or 2014.
	Goodwill and Indefinite-lived Intangible Assets – Goodwill and other indefinite lived intangible assets recorded are not amortized but are periodically tested for impairment. The Company assesses goodwill for impairment on the last day of each fiscal year, or more frequently if certain events occur as described above. Goodwill is evaluated for impairment through the comparison of the fair value of the reporting units to their carrying values. When evaluating goodwill for impairment, the Company may first perform an assessment of qualitative factors to determine if the fair value of the reporting unit is more-likely-than-not greater than its carrying amount. This qualitative assessment is referred to as a “step zero” approach. If, based on the review of the qualitative factors, the Company determines it is more-likely-than-not that the fair value of the reporting unit is greater than its carrying value, the required two-step impairment test can be bypassed. If the Company does not perform a step zero assessment or if the fair value of the reporting unit is more-likely-than-not less than its carrying value, the Company must perform a two-step impairment test, and calculate the estimated fair value of the reporting unit. If, based upon the two-step impairment test, it is determined that the fair value of a reporting unit is less than its carrying value, an impairment loss is recorded to the extent that the implied fair value of the goodwill within the reporting unit is less than its carrying value. Under the two-step approach, fair values for reporting units are determined based on discounted cash flows and market multiples.
	Other indefinite lived intangible assets are assessed for impairment on the last day of each fiscal year, or more frequently if certain events occur as described above, by comparing the fair value of the intangible asset to its carrying value. The fair value is determined by using the income approach.
	The Company did not record any impairment charges related to its indefinite-lived intangible assets, including goodwill, during the first three months of 2015 or 2014, respectively. See Note 5 “Intangible Assets” for additional information on the Company’s intangible assets.
	Cost and Equity Method Investments – The Company holds investments in equity and other securities that are accounted for as either cost or equity method investments, which are classified as Other Assets. The total carrying value of these investments is reviewed quarterly for changes in circumstance or the occurrence of events that suggest the Company’s investment may not be recoverable. The fair value of cost or equity method investments is not adjusted if there are no identified events or changes in circumstances that may have a material effect on the fair value of the investments. Gains and losses realized on cost and equity method investments are recorded in Other Income, Net, unless separately stated. The aggregate recorded amount of cost and equity method investments at April 3, 2015 and January 2, 2015 was $17.0 million and $14.5 million, respectively. The Company’s equity method investment is in a Chinese venture capital fund focused on investing in life sciences companies. This fund accounts for its investments at fair value with the unrealized change in fair value of these investments recorded as income or loss to the fund in the period of change. As of April 3, 2015, the Company owned 7.3% of this fund.
	During the first quarter of 2015 and 2014, the Company did not recognize any impairment charges related to its cost method investments. The fair value of these investments is determined by reference to recent sales data of similar shares to independent parties in an inactive market. This fair calculation is categorized in Level 2 of the fair value hierarchy. During the first quarter of 2015 and 2014, the Company recognized a net gain on equity method investments of $0.5 million and $0.8 million, respectively.

Business_Segment_Geographic_an

Business Segment, Geographic and Concentration Risk Information	3 Months Ended
	Apr. 03, 2015
Segment Reporting [Abstract]
BUSINESS SEGMENT, GEOGRAPHIC AND CONCENTRATION RISK INFORMATION	BUSINESS SEGMENT, GEOGRAPHIC AND CONCENTRATION RISK INFORMATION
	The Company has two reportable segments: Greatbatch Medical and QiG. Greatbatch Medical designs and manufactures medical devices and components where Greatbatch either owns the intellectual property or has unique manufacturing and assembly expertise. Greatbatch Medical provides medical devices and components to the following markets:
	•	Cardiac/Neuromodulation: Products include batteries, capacitors, filtered and unfiltered feed-throughs, engineered components, implantable stimulation leads, and enclosures used in implantable medical devices.
	•	Orthopaedic: Products include implants, instruments and delivery systems for large joint, spine, extremity and trauma procedures.
	•	Portable Medical: Products include automated external defibrillators, portable oxygen concentrators, ventilators, and powered surgical tools.
	•	Vascular: Products include introducers, steerable sheaths, and catheters that deliver therapies for various markets such as coronary and neurovascular disease, peripheral vascular disease, interventional radiology, vascular access, atrial fibrillation, and interventional cardiology, plus products for medical imaging and pharmaceutical delivery.
	•	Energy, Military, and Environmental: Products include primary and rechargeable batteries and battery packs for demanding applications such as down hole drilling tools.
	Greatbatch Medical also offers value-added assembly and design engineering services for medical devices that utilize its component products.
	QiG focuses on developing medical device systems for some of healthcare’s most pressing challenges and reflects Greatbatch’s strategic evolution of its product offerings in order to raise the growth and profitability profile of the Company. QiG utilizes a disciplined and diversified portfolio approach with three investment modes: new medical device systems commercialization, collaborative programs with original equipment manufacturers (“OEM”) customers, and strategic equity positions in emerging healthcare companies. The development of certain new medical device systems are facilitated through the establishment of limited liability companies (“LLCs”). These LLCs do not own, but have the exclusive right to use the technology of Greatbatch in certain, specific fields of use and have an exclusive manufacturing agreement with Greatbatch Medical. QiG currently owns 89% - 100% of three LLCs. Minority interest in these LLCs are held by key opinion leaders, clinicians and strategic partners. Under the agreements governing these LLCs, QiG is responsible for 100% of the expenses incurred by the LLC. However, no distributions are made to the minority holders until QiG is reimbursed for all expenses paid. Once QiG has been fully reimbursed, all future distributions are made based upon the respective LLCs ownership percentages.
	One of the LLCs owned by QiG is Algostim, which was established in 2008 to design and develop a broad-based neurostimulation platform. Algostim’s Algovita Spinal Cord Stimulation (“SCS”) system is the first application of QiG’s neurostimulation platform, with additional QiG applications currently in development. Algovita was submitted for premarket approval (“PMA”) to the United States Food & Drug Administration (“FDA”) in December 2013 and in January 2014 documentation for European CE Mark was submitted to the notified body, TÜV SÜD America. CE Mark approval was obtained on June 17, 2014. During the first quarter of 2015, Greatbatch was informed by the FDA that it has determined that the PMA application is approvable subject to an FDA inspection that finds the manufacturing facilities, methods and controls in compliance with the applicable requirements of the Quality System regulation. On April 30, 2015, the Company announced its proposal to spin-off Algostim. The spin-off would create a new publicly traded company focused on commercializing the Algovita SCS system to treat chronic intractable pain of the trunk and/or limbs, with Greatbatch Medical continuing to manufacture Algovita under a long term supply agreement with the new public company.
	QiG revenue includes sales of neural interface technology, components and systems to the neuroscience and clinical markets, and a limited release of Algovita in Europe. As further discussed in Note 2 “Acquisition,” in August 2014, the Company acquired CCC, a neuromodulation medical device developer and manufacturer for development stage companies. As a result of this transaction, QiG revenue for 2015 also includes sales of various medical device products such as implantable pulse generators, programmer systems, battery chargers, patient wands and leads to medical device companies. In addition to the above, future income of QiG is expected to come from various other sources including investment gains from sales of its LLC ownership interests, technology licensing fees, royalty revenue, and/or the sales of medical device systems.
	An analysis and reconciliation of the Company’s business segment, product line and geographic information to the respective information in the Condensed Consolidated Financial Statements follows. Sales by geographic area are presented by allocating sales from external customers based on where the products are shipped to (in thousands):
		Three Months Ended
		3-Apr-15				4-Apr-14
	Sales:
	Greatbatch Medical
	Cardiac/Neuromodulation	$	76,273			$	86,780
	Orthopaedic	38,971				36,431
	Portable Medical	13,667				19,203
	Vascular	10,356				13,050
	Energy, Military, Environmental	17,710				18,131
	Total Greatbatch Medical	156,977				173,595
	QiG	5,047				686
	Elimination of Intersegment Sales(a)	(704		)		—
	Total sales	$	161,320			$	174,281
	(a)	Intersegment sales between Greatbatch Medical and QiG are eliminated in consolidation and are included in Greatbatch Medical’s cardiac and neuromodulation product line.
		Three Months Ended
		3-Apr-15				4-Apr-14
	Segment income from operations:
	Greatbatch Medical	$	21,753			$	35,128
	QiG	(5,450		)		(5,913		)
	Total segment income from operations	16,303				29,215
	Unallocated operating expenses	(6,914		)		(6,691		)
	Operating income as reported	9,389				22,524
	Unallocated other income (expense)	431				(463		)
	Income before provision for income taxes	$	9,820			$	22,061
		Three Months Ended
		3-Apr-15				4-Apr-14
	Sales by geographic area:
	United States	$	70,516			$	81,112
	Non-Domestic locations:
	Puerto Rico	34,016				34,598
	Belgium	17,367				15,979
	Rest of world	39,421				42,592
	Total sales	$	161,320			$	174,281
	Three customers accounted for a significant portion of the Company’s sales as follows:
		Three Months Ended
		3-Apr-15			4-Apr-14
	Customer A	22	%		21	%
	Customer B	18	%		15	%
	Customer C	14	%		12	%
	Total	54	%		48	%
	Long-lived tangible assets by geographic area are as follows (in thousands):
		As of
		3-Apr-15				2-Jan-15
	United States	$	113,067			$	113,851
	Rest of world	38,283				31,074
	Total	$	151,350			$	144,925

Impact_of_Recently_Issued_Acco

Impact of Recently Issued Accounting Standards	3 Months Ended
	Apr. 03, 2015
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
IMPACT OF RECENTLY ISSUED ACCOUNTING STANDARDS	IMPACT OF RECENTLY ISSUED ACCOUNTING STANDARDS
	In the normal course of business, management evaluates all new accounting pronouncements issued by the Financial Accounting Standards Board (“FASB”), Securities and Exchange Commission (“SEC”), Emerging Issues Task Force (“EITF”), or other authoritative accounting bodies to determine the potential impact they may have on the Company’s Condensed Consolidated Financial Statements. Based upon this review, except as noted below, management does not expect any of the recently issued accounting pronouncements, which have not already been adopted, to have a material impact on the Company’s Condensed Consolidated Financial Statements.
	In April 2015, the FASB issued Accounting Standards Update (“ASU”) 2015-03, “Interest-Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs,” which changes the presentation of debt issuance costs in the financial statements. Under this ASU, the Company will present debt issuance costs in the balance sheet as a direct deduction from the related debt liability rather than as an asset. The guidance in this ASU is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. The Company will apply the new guidance retrospectively to all prior periods presented beginning in the first quarter of
	fiscal year 2016. As disclosed in Note 6 “Debt,” as of April 3, 2015, the Company had $2.9 million of debt related deferred financing costs recorded within Other Assets in the Condensed Consolidated Balance Sheet, which will be reclassified as a deduction from Long-Term Debt upon adoption of this ASU.
	In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers.” The core principle behind ASU 2014-09 is that an entity should recognize revenue in an amount that reflects the consideration to which the entity expects to be entitled in exchange for delivering goods and services. This model involves a five-step process that includes identifying the contract with the customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations in the contract and recognizing revenue when the entity satisfies the performance obligations. This ASU will supersede existing revenue recognition guidance and is effective for annual reporting periods beginning after December 15, 2017, with early application not permitted. This ASU allows two methods of adoption; a full retrospective approach where three years of financial information are presented in accordance with the new standard, and a modified retrospective approach where this ASU is applied to the most current period presented in the financial statements. The Company is currently assessing the financial impact of adopting the new standard and the methods of adoption; however, given the scope of the new standard, the company is currently unable to provide a reasonable estimate regarding the financial impact or which method of adoption will be elected.
	In April 2014, the FASB issued ASU No. 2014-08, “Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity,” which amends the definition of a discontinued operation and requires entities to provide additional disclosures about disposal transactions that do not meet the discontinued operations criteria. The revised guidance changes how entities identify and disclose information about disposal transactions under U.S. GAAP. This ASU is effective prospectively for all disposals (except disposals classified as held for sale before the adoption date) or components initially classified as held for sale in periods beginning on or after December 15, 2014, with early adoption permitted. This ASU is applicable for disposal transactions, if any, that the Company enters into after January 2, 2015, and did not materially impact the Company’s Condensed Consolidated Financial Statements.

Accounting_Policies_Policies

Accounting Policies (Policies)	3 Months Ended
	Apr. 03, 2015
Accounting Policies [Abstract]
Interim Basis of Accounting	The January 2, 2015 condensed consolidated balance sheet data was derived from audited consolidated financial statements but does not include all disclosures required by GAAP. For further information, refer to the consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended January 2, 2015.
	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information (Accounting Standards Codification (“ASC”) 270, Interim Reporting) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information necessary for a full presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. In the opinion of management, the condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the results of Greatbatch, Inc. and its wholly-owned subsidiary, Greatbatch Ltd. (collectively “Greatbatch” or the “Company”), for the periods presented.
Use of Estimates	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, sales, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ materially from these estimates.
Fiscal Period	The Company utilizes a fifty-two, fifty-three week fiscal year ending on the Friday nearest December 31. The first quarter of 2015 and 2014 each contained 13 weeks and ended on April 3, and April 4, respectively.
Income Taxes	The income tax provision for interim periods is determined using an estimate of the annual effective tax rate, adjusted for discrete items, if any, that are taken into account in the relevant period. Each quarter, the estimate of the annual effective tax rate is updated, and if the estimated effective tax rate changes, a cumulative adjustment is made. There is a potential for volatility of the effective tax rate due to several factors, including changes in the mix of the pre-tax income and the jurisdictions to which it relates, changes in tax laws and foreign tax holidays, business reorganizations, settlements with taxing authorities and foreign currency fluctuations.
Long Lived Assets and Finite Lived Intangible Assets	The Company reviews the carrying amount of its long-lived assets to be held and used, other than goodwill and indefinite-lived intangible assets, for potential impairment whenever certain indicators are present such as: a significant decrease in the market price of the asset or asset group; a significant change in the extent or manner in which the long-lived asset or asset group is being used or in its physical condition; a significant change in legal factors or in the business climate that could affect the value of the long-lived asset or asset group, including an action or assessment by a regulator; an accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction; a current-period operating or cash flow loss combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with the use of the long-lived asset or asset group; or a current expectation that, more likely than not, a long-lived asset or asset group will be sold or otherwise disposed of significantly before the end of its previously estimated useful life. The term more likely than not refers to a level of likelihood that is more than 50 percent.
	Potential recoverability is measured by comparing the carrying amount of the asset or asset group to its related total future undiscounted cash flows. If the carrying value is not recoverable, the asset or asset group is considered to be impaired. Impairment is measured by comparing the asset or asset group’s carrying amount to its fair value. When it is determined that useful lives are shorter than originally estimated, and no impairment is present, the rate of depreciation is accelerated in order to fully depreciate the assets over their new shorter useful lives. The Company did not record any impairment charges related to its long-lived assets during the first three months of 2015 or 2014.
Goodwill and Intangible Assets	Goodwill and other indefinite lived intangible assets recorded are not amortized but are periodically tested for impairment. The Company assesses goodwill for impairment on the last day of each fiscal year, or more frequently if certain events occur as described above. Goodwill is evaluated for impairment through the comparison of the fair value of the reporting units to their carrying values. When evaluating goodwill for impairment, the Company may first perform an assessment of qualitative factors to determine if the fair value of the reporting unit is more-likely-than-not greater than its carrying amount. This qualitative assessment is referred to as a “step zero” approach. If, based on the review of the qualitative factors, the Company determines it is more-likely-than-not that the fair value of the reporting unit is greater than its carrying value, the required two-step impairment test can be bypassed. If the Company does not perform a step zero assessment or if the fair value of the reporting unit is more-likely-than-not less than its carrying value, the Company must perform a two-step impairment test, and calculate the estimated fair value of the reporting unit. If, based upon the two-step impairment test, it is determined that the fair value of a reporting unit is less than its carrying value, an impairment loss is recorded to the extent that the implied fair value of the goodwill within the reporting unit is less than its carrying value. Under the two-step approach, fair values for reporting units are determined based on discounted cash flows and market multiples.
	Other indefinite lived intangible assets are assessed for impairment on the last day of each fiscal year, or more frequently if certain events occur as described above, by comparing the fair value of the intangible asset to its carrying value. The fair value is determined by using the income approach.
Cost And Equity Method Investments	The Company holds investments in equity and other securities that are accounted for as either cost or equity method investments, which are classified as Other Assets. The total carrying value of these investments is reviewed quarterly for changes in circumstance or the occurrence of events that suggest the Company’s investment may not be recoverable. The fair value of cost or equity method investments is not adjusted if there are no identified events or changes in circumstances that may have a material effect on the fair value of the investments. Gains and losses realized on cost and equity method investments are recorded in Other Income, Net, unless separately stated.

Acquisition_Tables

Acquisition (Tables)	3 Months Ended
	Apr. 03, 2015
Business Combinations [Abstract]
Summary of Assets Acquired and Liabilities Assumed	The following table summarizes the allocation of the CCC purchase price to the assets acquired and liabilities assumed as of the acquisition date (in thousands):
	Assets acquired
	Current assets	$	10,670
	Property, plant and equipment	1,131
	Amortizing intangible assets	6,100
	Goodwill	8,296
	Total assets acquired	26,197
	Liabilities assumed
	Current liabilities	4,842
	Deferred income taxes	1,590
	Total liabilities assumed	6,432
	Net assets acquired	$	19,765
Summary of Finite-Lived Intangibles Assets Acquired	The purchase price was allocated to intangible assets as follows (dollars in thousands):
	Amortizing Intangible Assets		Fair			Weighted	Weighted
			Value			Average	Average
			Assigned			Amortization	Discount
						Period (Years)	Rate
	Technology		$	1,400		10	18%
	Customer lists		4,600			10	18%
	Trademarks and tradenames		100			2	18%
			$	6,100		10	18%
Summary of Acquisition Pro Forma Results	The following unaudited pro forma information presents the consolidated results of operations of the Company and CCC as if that acquisition occurred as of the beginning of fiscal year 2013 (in thousands, except per share amounts):
		Three Months Ended
		3-Apr-15			4-Apr-14
	Sales	$	161,320		$	177,709
	Net income	8,008			15,258
	Earnings per share:
	Basic	$	0.32		$	0.62
	Diluted	$	0.31		$	0.59

Supplemental_Cash_Flow_Informa1

Supplemental Cash Flow Information (Tables)	3 Months Ended
	Apr. 03, 2015
Supplemental Cash Flow Elements [Abstract]
Schedule of Cash Flow, Supplemental Disclosures
		Three Months Ended
	(in thousands)	April 3, 2015		April 4, 2014
	Noncash investing and financing activities:
	Common stock contributed to 401(k) Plan	$	3,920	$	4,341
	Property, plant and equipment purchases included in accounts payable	943		1,180

Inventories_Tables

Inventories (Tables)	3 Months Ended
	Apr. 03, 2015
Inventory Disclosure [Abstract]
Schedule of Inventory, Current	Inventories are comprised of the following (in thousands):
		As of
		3-Apr-15		2-Jan-15
	Raw materials	$	76,738	$	73,354
	Work-in-process	43,402		38,930
	Finished goods	17,849		16,958
	Total	$	137,989	$	129,242

Intangible_Assets_Tables

Intangible Assets (Tables)	3 Months Ended
	Apr. 03, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets by Major Class	Amortizing intangible assets are comprised of the following (in thousands):
		Gross			Accumulated			Foreign			Net
		Carrying			Amortization			Currency			Carrying
		Amount						Translation			Amount
	At April 3, 2015
	Purchased technology and patents	$	95,776		$	(77,468	)	$	1,966		$	20,274
	Customer lists	72,857			(33,208		)	1,374			41,023
	Other	4,534			(4,684		)	803			653
	Total amortizing intangible assets	$	173,167		$	(115,360	)	$	4,143		$	61,950
	At January 2, 2015
	Purchased technology and patents	$	95,776		$	(75,894	)	$	1,966		$	21,848
	Customer lists	72,857			(31,460		)	1,374			42,771
	Other	4,534			(4,619		)	803			718
	Total amortizing intangible assets	$	173,167		$	(111,973	)	$	4,143		$	65,337
Schedule of Finite-Lived Intangible Assets, Amortization Expense	Aggregate intangible asset amortization expense is comprised of the following (in thousands):
		Three Months Ended
		3-Apr-15			4-Apr-14
	Cost of sales	$	1,471		$	1,563
	Selling, general and administrative expenses	1,813			1,717
	Research, development and engineering costs, net	103			201
	Total intangible asset amortization expense	$	3,387		$	3,481
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	Estimated future intangible asset amortization expense based on the current carrying value is as follows (in thousands):
		Estimated
		Amortization
		Expense
	Remainder of 2015	$	9,600
	2016	10,795
	2017	9,520
	2018	7,114
	2019	5,431
	Thereafter	19,490
	Total estimated amortization expense	$	61,950
Schedule of Intangible Assets Goodwill	Indefinite-lived intangible assets are comprised of the following (in thousands):
		Trademarks
		and
		Tradenames
	At January 2, 2015	$	20,288
	At April 3, 2015	$	20,288
	The change in goodwill is as follows (in thousands):
		Greatbatch Medical			QiG			Total
	At January 2, 2015	$	304,297		$	50,096		$	354,393
	Foreign currency translation	(332		)	—			(332		)
	At April 3, 2015	$	303,965		$	50,096		$	354,061

Debt_Tables

Debt (Tables)	3 Months Ended
	Apr. 03, 2015
Debt Disclosure [Abstract]
Schedule of Debt	Long-term debt is comprised of the following (in thousands):
		As of
		3-Apr-15				2-Jan-15
	Variable rate term loan	$	185,000			$	187,500
	Revolving line of credit	—				—
	Total debt	185,000				187,500
	Less current portion of long-term debt	12,500				11,250
	Total long-term debt	$	172,500			$	176,250
Schedule Of Interest Rate Derivatives	Information regarding the Company’s outstanding interest rate swaps as of April 3, 2015 is as follows (dollars in thousands):
	Instrument		Type of		Notional			Start	End	Pay		Current		Fair Value			Balance
			Hedge		Amount			Date	Date	Fixed		Receive					Sheet Location
										Rate		Floating
												Rate
	Interest rate swap		Cash flow		$	50,000		13-Feb	16-Feb	0.573	%	0.176	%	$	(127	)	Accrued Expenses
	Interest rate swap		Cash flow		$	90,000		15-Feb	19-Sep	1.921	%	0.176	%	$	(2,194	)	Other Long-Term Liabilities
Schedule Of Maturities Of Long Term Debt	The expected future minimum principal payments under the Term Loan as of April 3, 2015 are as follows (in thousands):
	Remainder of 2015	$	8,750
	2016	16,250
	2017	20,000
	2018	20,000
	2019	120,000
	Total	$	185,000
Schedule of Deferred Financing Costs	Deferred Financing Fees – The change in deferred financing fees is as follows (in thousands):
	At January 2, 2015	$	3,087
	Amortization during the period	(193		)
	At April 3, 2015	$	2,894

Benefit_Plans_Tables

Benefit Plans (Tables)	3 Months Ended
	Apr. 03, 2015
Defined Benefit Pension Plans and Defined Benefit Postretirement Plans Disclosure [Abstract]
Schedule of Defined Benefit Plans Disclosures	The change in net defined benefit plan liability is as follows (in thousands):
	At January 2, 2015	$	2,406
	Net defined benefit cost	105
	Foreign currency translation	(176		)
	At April 3, 2015	$	2,335
Schedule of Net Benefit Costs	Net defined benefit cost is comprised of the following (in thousands):
		Three Months Ended
		3-Apr-15			4-Apr-14
	Service cost	$	79		$	52
	Interest cost	15			19
	Amortization of net loss	14			6
	Expected return on plan assets	(3		)	—
	Net defined benefit cost	$	105		$	77

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	3 Months Ended
	Apr. 03, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs	The components and classification of stock-based compensation expense were as follows (in thousands):
		Three Months Ended
		3-Apr-15				4-Apr-14
	Stock options	$	619			$	604
	Restricted stock and restricted stock units	1,634				1,557
	401(k) Plan stock contribution	—				1,016
	Total stock-based compensation expense	$	2,253			$	3,177
	Cost of sales	$	260			$	911
	Selling, general and administrative expenses	1,761				1,923
	Research, development and engineering costs, net	232				343
	Total stock-based compensation expense	$	2,253			$	3,177
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	The weighted average fair value and assumptions used to value options granted are as follows:
		Three Months Ended
		3-Apr-15				4-Apr-14
	Weighted average fair value	$	12.07			$	16.41
	Risk-free interest rate	1.55		%		1.73		%
	Expected volatility	26		%		39		%
	Expected life (in years)	5				5
	Expected dividend yield	—		%		—		%
Schedule of Share-based Compensation, Stock Options, Activity	The following table summarizes time-vested stock option activity:
		Number of			Weighted				Weighted	Aggregate
		Time-Vested			Average				Average	Intrinsic
		Stock			Exercise				Remaining	Value
		Options			Price				Contractual	(In Millions)
									Life
									(In Years)
	Outstanding at January 2, 2015	1,471,498			$	25.32
	Granted	265,841			48.68
	Exercised	(159,229	)		23.2
	Forfeited or expired	(15,410	)		33.99
	Outstanding at April 3, 2015	1,562,700			$	29.43			6.6	$	42.7
	Exercisable at April 3, 2015	1,123,451			$	24.1			5.6	$	36.6
	The following table summarizes performance-vested stock option activity:
		Number of			Weighted				Weighted	Aggregate
		Performance-			Average				Average	Intrinsic
		Vested Stock			Exercise				Remaining	Value
		Options			Price				Contractual	(In Millions)
									Life
									(In Years)
	Outstanding at January 2, 2015	118,839			$	23.24
	Exercised	(22,637	)		22.71
	Outstanding at April 3, 2015	96,202			$	23.36			2.8	$	3.2
	Exercisable at April 3, 2015	96,202			$	23.36			2.8	$	3.2
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity	The following table summarizes time-vested restricted stock and restricted stock unit activity:
		Time-Vested			Weighted
		Activity			Average
					Fair Value
	Nonvested at January 2, 2015	67,832			$	36.22
	Granted	36,182			49.04
	Vested	(3,500	)		48.63
	Forfeited	(4,106	)		40.78
	Nonvested at April 3, 2015	96,408			$	40.39
	The following table summarizes performance-vested restricted stock and restricted stock unit activity:
		Performance-			Weighted
		Vested			Average
		Activity			Fair Value
	Nonvested at January 2, 2015	716,163			$	19.57
	Granted	179,940			32.92
	Vested	(270,198	)		15.3
	Forfeited	(14,585	)		24.67
	Nonvested at April 3, 2015	611,320			$	25.27

Other_Operating_Income_Expense1

Other Operating (Income) Expenses, Net (Tables)	3 Months Ended
	Apr. 03, 2015
Restructuring Cost and Reserve [Line Items]
Schedule Of Other Operating Cost and Expense By Component	Other Operating Expenses (Income), Net is comprised of the following (in thousands):
		Three Months Ended
		3-Apr-15			4-Apr-14
	2014 investments in capacity and capabilities	$	6,455		$	—
	Orthopaedic optimization costs (income)	473			(1,157		)
	2013 operating unit realignment	—			1,003
	Other consolidation and optimization income, net	—			(61		)
	Acquisition and integration costs (income)	66			(428		)
	Asset dispositions, severance and other	861			429
		$	7,855		$	(214	)
Investments in Capacity and Capabilities [Member]
Restructuring Cost and Reserve [Line Items]
Schedule of Restructuring Reserve by Type of Cost	The change in accrued liabilities related to the 2014 investments in capacity and capabilities is as follows (in thousands):
		Severance and			Accelerated			Other			Total
		Retention			Depreciation/Asset
					Write-offs
	At January 2, 2015	$	1,163		$	—		$	1,066		$	2,229
	Restructuring charges	549			—			5,906			6,455
	Cash payments	(100		)	—			(5,590		)	(5,690		)
	At April 3, 2015	$	1,612		$	—		$	1,382		$	2,994
Orthopaedic Facility Optimization [Member]
Restructuring Cost and Reserve [Line Items]
Schedule of Restructuring Reserve by Type of Cost	The change in accrued liabilities related to the orthopaedic facility optimization is as follows (in thousands):
		Severance			Accelerated			Other			Total
		and			Depreciation/Asset
		Retention			Write-offs
	At January 2, 2015	$	—		$	—		$	287		$	287
	Restructuring charges	—			—			473			473
	Cash payments	—			—			(473		)	(473		)
	At April 3, 2015	$	—		$	—		$	287		$	287

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	3 Months Ended
	Apr. 03, 2015
Commitments and Contingencies Disclosure [Abstract]
Schedule of Product Warranty Liability	The change in product warranty liability was comprised of the following (in thousands):
	At January 2, 2015	$	660
	Additions to warranty reserve	691
	Warranty claims paid	(72		)
	At April 3, 2015	$	1,279
Schedule of Future Minimum Rental Payments for Operating Leases	Minimum future estimated operating lease expenses are as follows (in thousands):
	Remainder of 2015	$	4,525
	2016	6,006
	2017	3,909
	2018	3,489
	2019	3,418
	Thereafter	13,938
	Total estimated operating lease expense	$	35,285
Schedule of Derivative Instruments, Gain (Loss) in Statement of Financial Performance	The impact to the Company’s results of operations from these forward contracts was as follows (in thousands):
		Three Months Ended
		3-Apr-15				4-Apr-14
	Addition (reduction) in cost of sales	$	244			$	(164	)
	Ineffective portion of change in fair value	—				—
Schedule of Foreign Exchange Contracts, Statement of Financial Position	Information regarding outstanding foreign currency contracts as of April 3, 2015 is as follows (dollars in thousands):
	Instrument		Type of		Aggregate		Start		End	$/Peso	Fair	Balance Sheet Location
			Hedge		Notional		Date		Date		Value
					Amount
	FX Contract		Cash flow		$12,660		15-Jan		15-Dec	0.0734	($1,128)	Accrued Expenses
	FX Contract		Cash flow		$2,360		15-Mar		15-Dec	0.0656	$45	Other Current Assets
	FX Contract		Cash flow		$15,081		16-Jan		16-Dec	0.0656	($77)	Other Long-Term Liabilities

Earnings_Per_Share_EPS_Tables

Earnings Per Share (EPS) (Tables)	3 Months Ended
	Apr. 03, 2015
Earnings Per Share [Abstract]
Schedule of Calculation of Numerator and Denominator in Earnings Per Share	The following table illustrates the calculation of Basic and Diluted EPS (in thousands, except per share amounts):
		Three Months Ended
		3-Apr-15			4-Apr-14
	Numerator for basic and diluted EPS:
	Net income	$	8,008		$	14,922
	Denominator for basic EPS:
	Weighted average shares outstanding	25,264			24,614
	Effect of dilutive securities:
	Stock options, restricted stock and restricted stock units	955			1,080
	Denominator for diluted EPS	26,219			25,694
	Basic EPS	$	0.32		$	0.61
	Diluted EPS	$	0.31		$	0.58
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The diluted weighted average share calculations do not include the following securities, which are not dilutive to the EPS calculations or the performance criteria have not been met:
		Three Months Ended
		3-Apr-15		4-Apr-14
	Time-vested stock options, restricted stock and restricted stock units	266,000		193,000
	Performance-vested restricted stock units	11,900		5,900

Accumulated_Other_Comprehensiv1

Accumulated Other Comprehensive Income (Tables)	3 Months Ended
	Apr. 03, 2015
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss)	Accumulated Other Comprehensive Income is comprised of the following (in thousands):
		Defined			Cash			Foreign			Total			Tax			Net-of-Tax
		Benefit			Flow			Currency			Pre-Tax						Amount
		Plan			Hedges			Translation			Amount
		Liability						Adjustment
	At January 2, 2015	$	(1,181	)	$	(2,558	)	$	11,450		$	7,711		$	1,412		$	9,123
	Unrealized loss on cash flow hedges	—			(1,347		)	—			(1,347		)	470			(877		)
	Realized loss on foreign currency hedges	—			244			—			244			(85		)	159
	Realized loss on interest rate swap hedges	—			181			—			181			(63		)	118
	Foreign currency translation loss	—			—			(1,825		)	(1,825		)	—			(1,825		)
	At April 3, 2015	$	(1,181	)	$	(3,480	)	$	9,625		$	4,964		$	1,734		$	6,698
		Defined			Cash			Foreign			Total			Tax			Net-of-Tax
		Benefit			Flow			Currency			Pre-Tax						Amount
		Plan			Hedges			Translation			Amount
		Liability						Adjustment
	At January 3, 2014	$	(672	)	$	(468	)	$	14,952		$	13,812		$	546		$	14,358
	Unrealized gain on cash flow hedges	—			150			—			150			(53		)	97
	Realized gain on foreign currency hedges	—			(164		)	—			(164		)	57			(107		)
	Realized loss on interest rate swap hedges	—			132			—			132			(45		)	87
	Foreign currency translation gain	—			—			1,182			1,182			—			1,182
	At April 4, 2014	$	(672	)	$	(350	)	$	16,134		$	15,112		$	505		$	15,617

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	3 Months Ended
	Apr. 03, 2015
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following table provides information regarding assets and liabilities recorded at fair value on a recurring basis (in thousands):
		Fair Value Measurements Using
		At		Quoted		Significant		Significant
		April 3,		Prices in		Other		Unobservable
				Active Markets		Observable		Inputs
				for Identical		Inputs
				Assets
	Description	2015		(Level 1)		(Level 2)		(Level 3)
	Assets
	Foreign currency contracts (Note 11)	$	45	$	—	$	45	$	—
	Liabilities
	Foreign currency contracts	$	1,205	$	—	$	1,205	$	—
	Interest rate swap (Note 6)	2,321		—		2,321		—

Business_Segment_Geographic_an1

Business Segment, Geographic and Concentration Risk Information (Tables)	3 Months Ended
	Apr. 03, 2015
Segment Reconciliation [Abstract]
Reconciliation of Revenue from Segments to Consolidated [Table Text Block]	Sales by geographic area are presented by allocating sales from external customers based on where the products are shipped to (in thousands):
		Three Months Ended
		3-Apr-15				4-Apr-14
	Sales:
	Greatbatch Medical
	Cardiac/Neuromodulation	$	76,273			$	86,780
	Orthopaedic	38,971				36,431
	Portable Medical	13,667				19,203
	Vascular	10,356				13,050
	Energy, Military, Environmental	17,710				18,131
	Total Greatbatch Medical	156,977				173,595
	QiG	5,047				686
	Elimination of Intersegment Sales(a)	(704		)		—
	Total sales	$	161,320			$	174,281
	(a)	Intersegment sales between Greatbatch Medical and QiG are eliminated in consolidation and are included in Greatbatch Medical’s cardiac and neuromodulation product line.
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]
		Three Months Ended
		3-Apr-15				4-Apr-14
	Segment income from operations:
	Greatbatch Medical	$	21,753			$	35,128
	QiG	(5,450		)		(5,913		)
	Total segment income from operations	16,303				29,215
	Unallocated operating expenses	(6,914		)		(6,691		)
	Operating income as reported	9,389				22,524
	Unallocated other income (expense)	431				(463		)
	Income before provision for income taxes	$	9,820			$	22,061
Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]	Three customers accounted for a significant portion of the Company’s sales as follows:
		Three Months Ended
		3-Apr-15			4-Apr-14
	Customer A	22	%		21	%
	Customer B	18	%		15	%
	Customer C	14	%		12	%
	Total	54	%		48	%
Geographic Areas, Revenues from External Customers [Abstract]
Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]
		Three Months Ended
		3-Apr-15				4-Apr-14
	Sales by geographic area:
	United States	$	70,516			$	81,112
	Non-Domestic locations:
	Puerto Rico	34,016				34,598
	Belgium	17,367				15,979
	Rest of world	39,421				42,592
	Total sales	$	161,320			$	174,281
Geographic Areas, Long-Lived Assets [Abstract]
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]	Long-lived tangible assets by geographic area are as follows (in thousands):
		As of
		3-Apr-15				2-Jan-15
	United States	$	113,067			$	113,851
	Rest of world	38,283				31,074
	Total	$	151,350			$	144,925

Basis_of_Presentation_Details

Basis of Presentation (Details)	3 Months Ended
	Apr. 03, 2015	Apr. 04, 2014
Accounting Policies [Abstract]
Fiscal Period Duration	91 days	91 days

Acquisition_Summary_of_Assets_

Acquisition (Summary of Assets Acquired and Liabilities Assumed) (Details) (USD $)	Apr. 03, 2015	Jan. 02, 2015	Aug. 12, 2014
In Thousands, unless otherwise specified
Assets acquired
Goodwill	$354,061	$354,393
CCC [Member]
Assets acquired
Current assets			10,670
Property, plant and equipment			1,131
Amortizing intangible assets			6,100
Goodwill			8,296
Total assets acquired			26,197
Liabilities assumed
Current liabilities			4,842
Deferred income taxes			1,590
Total liabilities assumed			6,432
Net assets acquired			$19,765

Acquisition_Summary_of_Intangi

Acquisition (Summary of Intangible Assets) (Details) (CCC [Member], USD $)	0 Months Ended
In Thousands, unless otherwise specified	Aug. 12, 2014
Acquired Finite-Lived Intangible Assets [Line Items]
Fair Value Assigned	$6,100
Weighted Average Amortization Period (Years)	10 years
Weighted Average Discount Rate	18.00%
Technology And Patents [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Royalty Rate (Percent)	3.00%
Fair Value Assigned	1,400
Weighted Average Amortization Period (Years)	10 years
Weighted Average Discount Rate	18.00%
Customer Lists [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Customer Annual Attrition Rate	15.00%
Fair Value Assigned	4,600
Weighted Average Amortization Period (Years)	10 years
Weighted Average Discount Rate	18.00%
Trademarks And Tradenames [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Royalty Rate (Percent)	0.50%
Fair Value Assigned	$100
Weighted Average Amortization Period (Years)	2 years
Weighted Average Discount Rate	18.00%

Acquisition_Pro_Forma_Informat

Acquisition (Pro Forma Information) (Details) (CCC [Member], USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Apr. 03, 2015	Apr. 04, 2014
CCC [Member]
Business Acquisition [Line Items]
Sales	$161,320	$177,709
Net income	$8,008	$15,258
Earnings per share:
Basic (in dollars per share)	$0.32	$0.62
Diluted (in dollars per share)	$0.31	$0.59

Acquisition_Narrative_Details

Acquisition (Narrative) (Details) (USD $)	0 Months Ended	3 Months Ended
In Millions, unless otherwise specified	Aug. 12, 2014	Apr. 03, 2015	Aug. 12, 2014
Business Acquisition [Line Items]
Name of acquired entity	Centro de Construcción de Cardioestimuladores del Uruguay (“CCC”)
Description of acquired entity	CCC is an active implantable neuromodulation medical device systems developer and manufacturer that produces a range of medical devices including implantable pulse generators, programmer systems, battery chargers, patient wands and leads.
Reason for acquisition	This acquisition allows the Company to more broadly partner with development stage medical device companies, complements the Company’s core discrete technology offerings and enhances the Company’s medical device innovation efforts.
CCC [Member]
Business Acquisition [Line Items]
Effective date of acquisition	12-Aug-14
Total revenue included from the acquired entity		$3.90
Total net income included from the acquired entity		0.1
Cash paid	19.8
Increase in inventory	$0.30		$0.30

Supplemental_Cash_Flow_Informa2

Supplemental Cash Flow Information (Details) (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Apr. 03, 2015	Apr. 04, 2014
Noncash investing and financing activities:
Common stock contributed to 401(k) Plan	$3,920	$4,341
Property, plant and equipment purchases included in accounts payable	$943	$1,180

Inventories_Details

Inventories (Details) (USD $)	Apr. 03, 2015	Jan. 02, 2015
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]
Inventory Raw Materials	$76,738	$73,354
Inventory, Work in Process	43,402	38,930
Inventory, Finished Goods	17,849	16,958
Inventories	$137,989	$129,242

Intangible_Assets_Amortizing_I

Intangible Assets (Amortizing Intangible Assets) (Details) (USD $)	Apr. 03, 2015	Jan. 02, 2015
In Thousands, unless otherwise specified
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$173,167	$173,167
Finite-Lived Intangible Assets, Accumulated Amortization	-115,360	-111,973
Foreign Currency Translation	4,143	4,143
Amortizing Intangible Assets, Net	61,950	65,337
Purchased Technology And Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	95,776	95,776
Finite-Lived Intangible Assets, Accumulated Amortization	-77,468	-75,894
Foreign Currency Translation	1,966	1,966
Amortizing Intangible Assets, Net	20,274	21,848
Customer Lists [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	72,857	72,857
Finite-Lived Intangible Assets, Accumulated Amortization	-33,208	-31,460
Foreign Currency Translation	1,374	1,374
Amortizing Intangible Assets, Net	41,023	42,771
Other Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	4,534	4,534
Finite-Lived Intangible Assets, Accumulated Amortization	-4,684	-4,619
Foreign Currency Translation	803	803
Amortizing Intangible Assets, Net	$653	$718

Intangible_Assets_Amortization

Intangible Assets (Amortization Expense by Categories) (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Apr. 03, 2015	Apr. 04, 2014	Jan. 02, 2015
Finite-Lived Intangible Assets [Line Items]
Finite Lived Intangible Assets, Amortization Expense	$3,387	$3,481
Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]
Remainder of 2015	9,600
2016	10,795
2017	9,520
2018	7,114
2019	5,431
Thereafter	19,490
Amortizing Intangible Assets, Net	61,950		65,337
Cost of Sales [Member]
Finite-Lived Intangible Assets [Line Items]
Finite Lived Intangible Assets, Amortization Expense	1,471	1,563
Selling General And Administrative Expense [Member]
Finite-Lived Intangible Assets [Line Items]
Finite Lived Intangible Assets, Amortization Expense	1,813	1,717
Research and Development Expense [Member]
Finite-Lived Intangible Assets [Line Items]
Finite Lived Intangible Assets, Amortization Expense	$103	$201

Intangible_Assets_Indefinite_L

Intangible Assets (Indefinite Lived Intangible Assets) (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Apr. 03, 2015	Jan. 02, 2015
Indefinite-lived Intangible Assets [Roll Forward]
Indefinite-Lived Intangible Assets, Beginning	$20,288
Indefinite-Lived Intangible Assets, Ending	20,288
Goodwill [Roll Forward]
Goodwill	354,393
Foreign currency translation	-332
Goodwill	354,061
Greatbatch Medical [Member]
Goodwill [Roll Forward]
Goodwill	304,297
Foreign currency translation	-332
Goodwill	303,965
QiG [Member]
Goodwill [Roll Forward]
Goodwill	50,096
Foreign currency translation	0
Goodwill	50,096
Trademarks And Tradenames [Member]
Indefinite-lived Intangible Assets [Roll Forward]
Indefinite-Lived Intangible Assets, Beginning		20,288
Indefinite-Lived Intangible Assets, Ending	$20,288	$20,288

Debt_Schedule_of_LongTerm_Debt

Debt (Schedule of Long-Term Debt) (Details) (USD $)	Apr. 03, 2015	Jan. 02, 2015
In Thousands, unless otherwise specified
Debt Disclosure [Abstract]
Variable rate term loan	$185,000	$187,500
Revolving line of credit	0	0
Total debt	185,000	187,500
Less current portion of long-term debt	12,500	11,250
Total long-term debt	$172,500	$176,250

Debt_Credit_Facility_Details_D

Debt (Credit Facility Details) (Details) (USD $)	3 Months Ended
	Apr. 03, 2015
Line of Credit Facility [Abstract]
Credit Facility Maximum borrowing capacity	$300,000,000
Term loan maximum borrowing capacity	200,000,000
Letter of Credit Subfacility maximum borrowing capacity	15,000,000
Swingline Subfacility maximum borrowing capacity	15,000,000
Credit Facility borrowing capacity increase	200,000,000
Credit Facility expiration date	20-Sep-18
Line of credit expiration date	20-Sep-19
Maturity date	20-Sep-19
Collateral	The Credit Facility is secured by the Company’s non-realty assets including cash, accounts receivable and inventories.
Credit Facility interest margin above Prime minimum	0.00%
Credit Facility interest margin above Prime maximum	0.75%
Credit Facility interest margin above LIBOR minimum	1.38%
Credit Facility interest margin above LIBOR maximum	2.75%
Swingline interest margin above Prime minimum	0.00%
Swingline interest margin above Prime maximum	0.75%
Line of credit facility minimum commitment fee, percentage	0.18%
Line of credit facility maximum commitment fee, percentage	0.25%
Credit Facility aggregate restricted activities limit	300,000,000
Credit Facility maximum permitted acquisitions	250,000,000
Credit Facility maximum investment purchases	100,000,000
Credit Facility maximum stock repurchase and dividends declared	150,000,000
Credit Facility maximum foreign subsidiary investment	20,000,000
Line of Credit adjustment to limitations to maximum leverage ratio	2.75
Credit Facility available restriction	100.00%
Credit Facility remaining restricted activities limit	275,000,000
Credit Facility remaining maximum permitted acquisitions	230,000,000
Credit Facility Maximum Oth Investment Purchases Remaining	95,000,000
Line of Credit Covenant, Adjusted EBITDA to Interest Expense, Ratio Required	3
Line of Credit Covenant, Leverage Ratio, Maximum	4.5
Line of Credit Covenant, Leverage Ratio, Maximum, As of Covenant Restrictive Effective Date	4.25
Total Leverage Covenant Restriction Effective Date	2-Jan-16
Debt Instrument, Covenant Compliance	As of April 3, 2015, the Company was in compliance with all covenants under the Credit Facility
Debt Weighted Average Interest Rate	1.57%
Unused borrowing capacity	$300,000,000

Debt_Convertible_Notes_and_Int

Debt (Convertible Notes and Interest Rate Swap Details) (Details) (USD $)	3 Months Ended		12 Months Ended
	Apr. 03, 2015	Apr. 04, 2014	Dec. 28, 2012
Derivative [Line Items]
Interest expense	$1,120,000	$1,084,000
Interest Rate Swap [Member]
Derivative [Line Items]
Gain (Loss) Recognized In Income Ineffective Portion	0	0
Interest expense	200,000	100,000
Description Of Interest Rate Risk Exposure	From time to time, the Company enters into interest rate swap agreements in order to hedge against potential changes in cash flows on the outstanding borrowings on the Credit Facility.
Description Of Interest Rate Cash Flow Hedge Accounting Method	These swaps are being accounted for as cash flow hedges.
Interest Rate Swap 1 [Member]
Derivative [Line Items]
Derivative, Term of Contract			3 years
Notional Amount	50,000,000		150,000,000
Type of Hedge	Interest rate swap
Start Date	20-Feb-13
End Date	22-Feb-16
Pay Fixed Interest Rate	0.57%
Current Receive Variable Interest Rate	0.18%
Annual Notional Amortizing Amount	50,000,000
Description Of Interest Rate Cash Flow Hedge Accounting Method	Cash flow
Interest Rate Swap 1 [Member] | Accrued Expenses [Member]
Derivative [Line Items]
Fair Value	-127,000
Interest Rate Swap 2 [Member]
Derivative [Line Items]
Notional Amount	90,000,000
Type of Hedge	Interest rate swap
End Date	20-Sep-19
Pay Fixed Interest Rate	1.92%
Current Receive Variable Interest Rate	0.18%
Annual Notional Amortizing Amount	10,000,000
Notional amortizing start date	21-Feb-17
Description Of Interest Rate Cash Flow Hedge Accounting Method	Cash flow
Interest Rate Swap 2 [Member] | Other Long-Term Liabilities [Member]
Derivative [Line Items]
Fair Value	-2,194,000
Interest Rate Swap 2a [Member]
Derivative [Line Items]
Notional Amount	45,000,000
Start Date	20-Feb-15
Interest Rate Swap 2b [Member]
Derivative [Line Items]
Notional Amount	$45,000,000
Start Date	22-Feb-16

Debt_Longterm_Debt_Maturity_Sc

Debt (Long-term Debt Maturity Schedule) (Details) (USD $)	Apr. 03, 2015	Jan. 02, 2015
In Thousands, unless otherwise specified
Long-term Debt, Fiscal Year Maturity [Abstract]
Remainder of 2015	$8,750
2016	16,250
2017	20,000
2018	20,000
2019	120,000
Total debt	$185,000	$187,500

Debt_Deferred_Financing_Fees_D

Debt (Deferred Financing Fees) (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Apr. 03, 2015
Deferred Finance Costs [Roll Forward]
Deferred Finance Costs, Net, Beginning Balance	$3,087
Amortization during the period	-193
Deferred Finance Costs, Net, Ending Balance	$2,894

Benefit_Plans_Benefit_Obligati

Benefit Plans (Benefit Obligation Roll Forward) (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Apr. 03, 2015	Apr. 04, 2014
Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]
At January 2, 2015	$2,406
Net defined benefit cost	105	77
Foreign currency translation	-176
At April 3, 2015	$2,335

Benefit_Plans_Defined_Benefit_

Benefit Plans (Defined Benefit Plan Costs) (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Apr. 03, 2015	Apr. 04, 2014
Defined Benefit Pension Plans and Defined Benefit Postretirement Plans Disclosure [Abstract]
Service cost	$79	$52
Interest cost	15	19
Amortization of net loss	14	6
Expected return on plan assets	-3	0
Net defined benefit cost	$105	$77

StockBased_Compensation_Expens

Stock-Based Compensation (Expense Details) (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Apr. 03, 2015	Apr. 04, 2014
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	$2,253	$3,177
Stock Option [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	619	604
Restricted Stock And Unit Awards [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	1,634	1,557
Retirement Plan [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	0	1,016
Cost of Sales [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	260	911
Selling General And Administrative Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	1,761	1,923
Research and Development Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	$232	$343

StockBased_Compensation_Fair_V

Stock-Based Compensation (Fair Value Assumptions) (Details) (USD $)	3 Months Ended
	Apr. 03, 2015	Apr. 04, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Weighted average fair value	$12.07	$16.41
Risk-free interest rate	1.55%	1.73%
Expected volatility	26.00%	39.00%
Expected life (in years)	5 years 0 months 0 days	5 years 0 months 0 days
Expected dividend yield	0.00%	0.00%

StockBased_Compensation_Stock_

Stock-Based Compensation (Stock Option Activity) (Details) (USD $)	3 Months Ended
In Millions, except Share data, unless otherwise specified	Apr. 03, 2015
Stock Options Time Based [Member]
Stock Option Activity (in shares)
Options Outstanding, Beginning	1,471,498
Granted	265,841
Exercised	-159,229
Forfeited or expired	-15,410
Options Outstanding, Ending	1,562,700
Options Exercisable	1,123,451
Weighted Average Exercise Price (in dollars per share)
Options Outstanding, Beginning	$25.32
Granted	$48.68
Exercised	$23.20
Forfeited or expired	$33.99
Options Outstanding, Ending	$29.43
Options Exercisable	$24.10
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Options Outstanding, Weighted Average Remaining Contractual Term	6 years 7 months 0 days
Options Exercisable, Weighted Average Remaining Contractual Term	5 years 7 months 0 days
Options Outstanding, Intrinsic Value	$42.70
Options Exercisable, Intrinsic Value	36.6
Stock Options Performance Based [Member]
Stock Option Activity (in shares)
Options Outstanding, Beginning	118,839
Exercised	-22,637
Options Outstanding, Ending	96,202
Options Exercisable	96,202
Weighted Average Exercise Price (in dollars per share)
Options Outstanding, Beginning	$23.24
Exercised	$22.71
Options Outstanding, Ending	$23.36
Options Exercisable	$23.36
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Options Outstanding, Weighted Average Remaining Contractual Term	2 years 9 months 0 days
Options Exercisable, Weighted Average Remaining Contractual Term	2 years 9 months 0 days
Options Outstanding, Intrinsic Value	3.2
Options Exercisable, Intrinsic Value	$3.20

StockBased_Compensation_Stock_1

Stock-Based Compensation (Stock Award Activity) (Details) (USD $)	3 Months Ended
	Apr. 03, 2015
Restricted Stock And Restricted Stock Units Time Based [Member]
Restricted Stock and Restricted Stock Unit Activity (in shares)
Nonvested, Beginning	67,832
Granted	36,182
Vested	-3,500
Forfeited	-4,106
Nonvested, Ending	96,408
Restricted Stock and Restricted Stock Unit Weighted Average Fair Value (in dollars per share)
Nonvested, Beginning	$36.22
Granted	$49.04
Vested	$48.63
Forfeited	$40.78
Nonvested, Ending	$40.39
Restricted Stock And Restricted Stock Units Performance Based [Member]
Restricted Stock and Restricted Stock Unit Activity (in shares)
Nonvested, Beginning	716,163
Granted	179,940
Vested	-270,198
Forfeited	-14,585
Nonvested, Ending	611,320
Restricted Stock and Restricted Stock Unit Weighted Average Fair Value (in dollars per share)
Nonvested, Beginning	$19.57
Granted	$32.92
Vested	$15.30
Forfeited	$24.67
Nonvested, Ending	$25.27

Other_Operating_Income_Expense2

Other Operating (Income) Expenses, Net (Expense Categories) (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Apr. 03, 2015	Apr. 04, 2014
Other Operating Income Expense Detail [Line Items]
Other Operating (Income) Expenses, Net	$7,855	($214)
Investments in Capacity and Capabilities [Member]
Other Operating Income Expense Detail [Line Items]
Other Operating (Income) Expenses, Net	6,455	0
Orthopaedic Facility Optimization [Member]
Other Operating Income Expense Detail [Line Items]
Other Operating (Income) Expenses, Net	473	-1,157
Operating Unit Realignment [Member]
Other Operating Income Expense Detail [Line Items]
Other Operating (Income) Expenses, Net	0	1,003
Other Restructuring [Member]
Other Operating Income Expense Detail [Line Items]
Other Operating (Income) Expenses, Net	0	-61
Acquisition And Integration Costs [Member]
Other Operating Income Expense Detail [Line Items]
Other Operating (Income) Expenses, Net	66	-428
Asset Dispositions Severance And Other [Member]
Other Operating Income Expense Detail [Line Items]
Other Operating (Income) Expenses, Net	$861	$429

Other_Operating_Income_Expense3

Other Operating (Income) Expenses, Net (Restructuring Costs and Reserve Details) (Details) (USD $)	3 Months Ended			12 Months Ended
In Millions, unless otherwise specified	Apr. 03, 2015	Jan. 02, 2015	Apr. 04, 2014	Jan. 02, 2015
	building
Investments in Capacity and Capabilities [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Initiation Date	2014
Restructuring And Related Activities Capital Expenditures Incurred To Date	$13
Restructuring and Related Cost, Cost Incurred to Date	15.4
Investments in Capacity and Capabilities [Member] | Minimum [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring And Related Activities Expected Capital Expenditures	25
Restructuring and Related Cost, Expected Cost	29
Investments in Capacity and Capabilities [Member] | Minimum [Member] | Severance And Retention [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	7
Investments in Capacity and Capabilities [Member] | Minimum [Member] | Accelerated Depreciation And Asset Write Offs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	2
Investments in Capacity and Capabilities [Member] | Minimum [Member] | Other Restructuring [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	20
Investments in Capacity and Capabilities [Member] | Maximum [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring And Related Activities Expected Capital Expenditures	27
Restructuring and Related Cost, Expected Cost	34
Investments in Capacity and Capabilities [Member] | Maximum [Member] | Severance And Retention [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	9
Investments in Capacity and Capabilities [Member] | Maximum [Member] | Accelerated Depreciation And Asset Write Offs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	3
Investments in Capacity and Capabilities [Member] | Maximum [Member] | Other Restructuring [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	22
Orthopaedic Facility Optimization [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Initiation Date	2010
Restructuring And Related Activities Capital Expenditures Incurred To Date	25.3
Restructuring and Related Cost, Cost Incurred to Date	43
Restructuring and Related Costs, Facility Consolidations	2
Initiatives, Expected Period of Completion	3 years
Gain (Loss) on Disposition of Business			2.5
Assets Transferred to Held for Sale				2.1
Impairment of Long-Lived Assets to be Disposed of		0.4
Orthopaedic Facility Optimization [Member] | Severance And Retention [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	11
Orthopaedic Facility Optimization [Member] | Accelerated Depreciation And Asset Write Offs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	13
Orthopaedic Facility Optimization [Member] | Minimum [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring And Related Activities Expected Capital Expenditures	30
Restructuring and Related Cost, Expected Cost	45
Orthopaedic Facility Optimization [Member] | Minimum [Member] | Other Restructuring [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	21
Orthopaedic Facility Optimization [Member] | Maximum [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring And Related Activities Expected Capital Expenditures	35
Restructuring and Related Cost, Expected Cost	48
Orthopaedic Facility Optimization [Member] | Maximum [Member] | Other Restructuring [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	24
Operating Unit Realignment [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Initiation Date	2013
Restructuring and Related Cost, Cost Incurred to Date	6.6
Operating Unit Realignment [Member] | Severance And Retention [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Cost Incurred to Date	5
Operating Unit Realignment [Member] | Other Restructuring [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Cost Incurred to Date	1.6
Algostim, LLC Spin-Off [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Cost Incurred to Date	0.5
Algostim, LLC Spin-Off [Member] | Minimum [Member] | Other Restructuring [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	8
Algostim, LLC Spin-Off [Member] | Maximum [Member] | Other Restructuring [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	$12
Greatbatch Medical [Member]
Restructuring Cost and Reserve [Line Items]
Number of sales and marketing groups	1
Number of operations groups	1

Other_Operating_Income_Expense4

Other Operating (Income) Expenses, Net Changes in Accrued Liabilities (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Apr. 03, 2015
Investments in Capacity and Capabilities [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance	$2,229
Restructuring charges	6,455
Cash payments	-5,690
Restructuring Reserve, Ending Balance	2,994
Orthopaedic Facility Optimization [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance	287
Restructuring charges	473
Cash payments	-473
Restructuring Reserve, Ending Balance	287
Severance And Retention [Member] | Investments in Capacity and Capabilities [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance	1,163
Restructuring charges	549
Cash payments	-100
Restructuring Reserve, Ending Balance	1,612
Severance And Retention [Member] | Orthopaedic Facility Optimization [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance	0
Restructuring charges	0
Cash payments	0
Restructuring Reserve, Ending Balance	0
Accelerated Depreciation And Asset Write Offs [Member] | Investments in Capacity and Capabilities [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance	0
Restructuring charges	0
Cash payments	0
Restructuring Reserve, Ending Balance	0
Accelerated Depreciation And Asset Write Offs [Member] | Orthopaedic Facility Optimization [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance	0
Restructuring charges	0
Cash payments	0
Restructuring Reserve, Ending Balance	0
Other Restructuring [Member] | Investments in Capacity and Capabilities [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance	1,066
Restructuring charges	5,906
Cash payments	-5,590
Restructuring Reserve, Ending Balance	1,382
Other Restructuring [Member] | Orthopaedic Facility Optimization [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance	287
Restructuring charges	473
Cash payments	-473
Restructuring Reserve, Ending Balance	$287

Income_Taxes_Narratives_Detail

Income Taxes (Narratives) (Details) (USD $)	Apr. 03, 2015
In Millions, unless otherwise specified
Income Tax Disclosure [Abstract]
Unrecognized Tax Benefits	$1.90
Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit	0.5
Unrecognized Tax Benefits that Would Impact Effective Tax Rate	$1.50

Commitments_and_Contingencies_1

Commitments and Contingencies (Narratives) (Details) (USD $)	0 Months Ended		3 Months Ended
	Dec. 03, 2014	Dec. 21, 2012	Apr. 03, 2015
Loss Contingencies [Line Items]
Product warranty description			The Company generally warrants that its products will meet customer specifications and will be free from defects in materials and workmanship.
Purchase commitments description			Contractual obligations for purchase of goods or services are defined as agreements that are enforceable and legally binding on the Company and that specify all significant terms, including: fixed or minimum quantities to be purchased; fixed, minimum, or variable price provisions; and the approximate timing of the transaction. The Company’s purchase orders are normally based on its current manufacturing needs and are fulfilled by its vendors within short time horizons. The Company also enters into blanket orders with vendors that have preferred pricing and terms; however, these orders are normally cancelable without penalty.
Remaining minimum amount committed			40,600,000
Foreign currency contracts description			The Company has entered into forward contracts to purchase Mexican pesos in order to hedge the risk of peso-denominated payments associated with operations at its Tijuana, Mexico facility.
Maximum aggregate loss under medical stop loss insurance per employee			250,000
Self-insurance medical liability			1,500,000
Litigation One [Member]
Loss Contingencies [Line Items]
Lawsuit filing date		December 21, 2012
Domicile of litigation			113th Judicial District Court of Harris County, Texas
Allegations			The complaint sought damages alleging marketing and product defects and failure to warn, negligence and gross negligence relating to a product the Company manufactured and sold to a customer, one of the other named defendants. The Company’s customer, in turn, incorporated the Greatbatch product into its own product which it sold to a third party, another named defendant.
Dismissal date	3-Dec-14
Settlement agreement date			13-Feb-15

Commitments_and_Contingencies_2

Commitments and Contingencies (Product Warranty Rollforward) (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Apr. 03, 2015
Movement in Standard Product Warranty Accrual [Roll Forward]
At January 2, 2015	$660
Additions to warranty reserve	691
Warranty claims paid	-72
At April 3, 2015	$1,279

Commitments_and_Contingencies_3

Commitments and Contingencies (Future Lease Payments) (Details) (USD $)	Apr. 03, 2015
In Thousands, unless otherwise specified
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
Remainder of 2015	$4,525
2016	6,006
2017	3,909
2018	3,489
2019	3,418
Thereafter	13,938
Total estimated operating lease expense	$35,285

Commitments_and_Contingencies_4

Commitments and Contingencies (FX Contract Details) (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Apr. 03, 2015	Apr. 04, 2014
Foreign Currency Cash Flow Hedges [Abstract]
Addition (reduction) in cost of sales	$244	($164)
Ineffective portion of change in fair value	0	0
Fx Contract 1 [Member]
Foreign Currency Cash Flow Hedge [Line Items]
Instrument	FX Contract
Aggregate Notional Amount	12,660
Start Date	1-Jan-15
End Date	31-Dec-15
$/Peso	0.0734
Fx Contract 2 [Member]
Foreign Currency Cash Flow Hedge [Line Items]
Instrument	FX Contract
Aggregate Notional Amount	2,360
Start Date	1-Mar-15
End Date	31-Dec-15
$/Peso	0.0656
Fx Contract 3 [Member]
Foreign Currency Cash Flow Hedge [Line Items]
Instrument	FX Contract
Aggregate Notional Amount	15,081
Start Date	1-Jan-16
End Date	31-Dec-16
$/Peso	0.0656
Accrued Expenses [Member] | Fx Contract 1 [Member]
Foreign Currency Cash Flow Hedge [Line Items]
Foreign Currency Cash Flow Hedge Liability at Fair Value	-1,128
Prepaid Expenses and Other Current Assets [Member] | Fx Contract 2 [Member]
Foreign Currency Cash Flow Hedge [Line Items]
Foreign Currency Cash Flow Hedge Asset at Fair Value	45
Other Long-Term Liabilities [Member] | Fx Contract 3 [Member]
Foreign Currency Cash Flow Hedge [Line Items]
Foreign Currency Cash Flow Hedge Liability at Fair Value	($77)

Earnings_Per_Share_EPS_Details

Earnings Per Share (EPS) (Details) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Apr. 03, 2015	Apr. 04, 2014
Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]
Net income	$8,008	$14,922
Weighted Average Number of Shares Outstanding Reconciliation [Abstract]
Basic	25,264,000	24,614,000
Effect of dilutive securities stock options, restricted stock and restricted stock units	955,000	1,080,000
Denominator for diluted EPS	26,219,000	25,694,000
Basic EPS (in dollars per share)	$0.32	$0.61
Diluted EPS (in dollars per share)	$0.31	$0.58
Anitdilutive Securities Excluded From Earnings Per Share [Abstract]
Time-vested stock options, restricted stock and restricted stock units	266,000	193,000
Performance-vested stock options and restricted stock units	11,900	5,900

Accumulated_Other_Comprehensiv2

Accumulated Other Comprehensive Income (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Apr. 03, 2015	Apr. 04, 2014
Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Adjustment, before Tax, [Abstract]
Defined Benefit Plan Liability, Beginning	($1,181)	($672)
Defined Benefit Plan Liability, Ending	-1,181	-672
Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, before Tax [Abstract]
Cash Flow Hedges, Beginning	-2,558	-468
Unrealized gain (loss) on cash flow hedges	-1,347	150
Realized Gain Loss On Foreign Currency Contracts Before Tax	244	-164
Realized Gain Loss On Interest Rate Swaps Before Tax	181	132
Cash Flow Hedges, End	-3,480	-350
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax [Abstract]
Foreign Currency Translation Adjustment, Beginning	11,450	14,952
Net foreign currency translation gain (loss)	-1,825	1,182
Foreign Currency Translation Adjustment, End	9,625	16,134
Other Comprehensive Income (Loss), before Tax [Abstract]
Total Pre-Tax Amount, Beginning	7,711	13,812
Unrealized gain (loss) on cash flow hedges	-1,347	150
Realized gain loss on foreign currency hedges - before tax	244	-164
Realized gain loss on interest rate swaps - before tax	181	132
Net foreign currency translation gain (loss)	-1,825	1,182
Total Pre-Tax Amount, End	4,964	15,112
Other Comprehensive Income (Loss), Tax [Abstract]
Tax, Beginning	1,412	546
Unrealized gain (loss) on cash flow hedges	470	-53
Realized gain loss on foreign currency contracts - tax	-85	57
Realized gain loss on interest rate swap hedges - tax	-63	-45
Net foreign currency translation gain (loss)	0	0
Tax, End	1,734	505
Other Comprehensive Income (Loss), Net of Tax [Abstract]
Net-of-Tax Amount, Beginning	9,123	14,358
Unrealized gain (loss) on cash flow hedges, net of tax	-877	97
Realized gain loss on foreign currency hedges, net of tax	159	-107
Realized gain loss on interest rate swap hedges, net of tax	118	87
Foreign currency translation gain (loss)	-1,825	1,182
Net-of-Tax Amount, End	$6,698	$15,617

Fair_Value_Measurements_Fair_V

Fair Value Measurements Fair Value Measurements (Narratives) (Details) (USD $)	3 Months Ended
	Apr. 03, 2015	Apr. 04, 2014	Jan. 02, 2015
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months	$1,100,000
Long Lived Assets Impairment Loss	0	0
Goodwill, Impairment Loss	0	0
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)	0	0
Cost And Equity Method Investments Aggregate Carrying Amount	17,000,000		14,500,000
Fair Value, Inputs, Level 2 [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Cost-method Investments, Other than Temporary Impairment	$500,000	$800,000
Chinese Venture Capital Fund [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Equity Method Investment, Ownership Percentage	7.30%

Fair_Value_Measurements_Fair_V1

Fair Value Measurements Fair Value Measurements (Assets and Liabilities Recorded at Fair Value on Recurring Basis Details) (Details) (Fair Value, Measurements, Recurring [Member], USD $)	Apr. 03, 2015
In Thousands, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency contracts	$45
Foreign currency contracts	1,205
Interest rate swap	2,321
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency contracts	0
Foreign currency contracts	0
Interest rate swap	0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency contracts	45
Foreign currency contracts	1,205
Interest rate swap	2,321
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency contracts	0
Foreign currency contracts	0
Interest rate swap	$0

Recovered_Sheet1

Business Segment, Geographic And Concentration Risk Information (Segment Revenue by Categories) (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Apr. 03, 2015	Apr. 04, 2014
	Segment
Segment Reporting [Abstract]
Number of Reportable Segments	2
Segment Reporting, Revenue Reconciling Item [Line Items]
Sales Revenue, Net	$161,320	$174,281
Revenue, Major Customer [Line Items]
Revenue Major Customer Percent	54.00%	48.00%
Customer A [Member]
Revenue, Major Customer [Line Items]
Revenue Major Customer Percent	22.00%	21.00%
Customer B [Member]
Revenue, Major Customer [Line Items]
Revenue Major Customer Percent	18.00%	15.00%
Customer C [Member]
Revenue, Major Customer [Line Items]
Revenue Major Customer Percent	14.00%	12.00%
Customer Concentration Risk [Member] | Sales Revenue, Net [Member]
Revenue, Major Customer [Line Items]
Number of customers accounting for significant portion	3
United States [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Sales Revenue, Net	70,516	81,112
Puerto Rico [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Sales Revenue, Net	34,016	34,598
Belgium [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Sales Revenue, Net	17,367	15,979
Rest Of World [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Sales Revenue, Net	39,421	42,592
Greatbatch Medical [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Sales Revenue, Net	156,977	173,595
Greatbatch Medical [Member] | Cardiac Neuromodulation [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Sales Revenue, Net	76,273	86,780
Greatbatch Medical [Member] | Orthopaedic [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Sales Revenue, Net	38,971	36,431
Greatbatch Medical [Member] | Portable Medical [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Sales Revenue, Net	13,667	19,203
Greatbatch Medical [Member] | Vascular [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Sales Revenue, Net	10,356	13,050
Greatbatch Medical [Member] | EME and Other [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Sales Revenue, Net	17,710	18,131
QiG [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Controlling Interest, Number of Ownership Interests	3
Controlling Interest, Liability of Expenses Incurred, Percentage	100.00%
FDA submission date	16-Dec-13
CE submission date	10-Jan-14
CE Approval Date	17-Jun-14
Sales Revenue, Net	5,047	686
Intersegment Eliminations [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Sales Revenue, Net	($704)	$0
Minimum [Member] | QiG [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Noncontrolling Interest, Ownership Percentage by Parent	89.00%
Maximum [Member] | QiG [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Noncontrolling Interest, Ownership Percentage by Parent	100.00%

Recovered_Sheet2

Business Segment, Geographic And Concentration Risk Information (Segment Income From Operations) (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Apr. 03, 2015	Apr. 04, 2014
Segment Reporting Information [Line Items]
Operating income as reported	$9,389	$22,524
Unallocated Other Expense	431	-463
Income before provision for income taxes	9,820	22,061
Greatbatch Medical [Member]
Segment Reporting Information [Line Items]
Operating income as reported	21,753	35,128
QiG [Member]
Segment Reporting Information [Line Items]
Operating income as reported	-5,450	-5,913
Operating Segments [Member]
Segment Reporting Information [Line Items]
Operating income as reported	16,303	29,215
Segment Reconciling Items [Member]
Segment Reporting Information [Line Items]
Operating income as reported	($6,914)	($6,691)

Business_Segment_Geographic_An2

Business Segment, Geographic And Concentration Risk Information (Long-lived Assets by Category) (Details) (USD $)	Apr. 03, 2015	Jan. 02, 2015
In Thousands, unless otherwise specified
Segment Reporting, Asset Reconciling Item [Line Items]
Property, plant and equipment, net	$151,350	$144,925
United States [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Property, plant and equipment, net	113,067	113,851
Rest Of World [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Property, plant and equipment, net	$38,283	$31,074

Impact_of_Recently_Issued_Acco1

Impact of Recently Issued Accounting Standards Impact of Recently Issued Accounting Standards (Narrative) (Details) (USD $)	Apr. 03, 2015	Jan. 02, 2015
In Thousands, unless otherwise specified
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Deferred Finance Costs, Net	$2,894	$3,087